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Abstract
The network model of innovation widely adopted among researchers in the economics of science
and technology posits relatively porous boundaries between firms and academic research programs
and a bi-directional flow of inventions, personnel, and tacit knowledge between sites of university
and industry innovation. Moreover, the model suggests that these bi-directional flows should be
considered as mutual stimulation of research and invention in both industry and academe, operating
as a positive feedback loop. One side of this bi-directional flow – namely; the flow of inventions into
industry through the licensing of university-based technologies – has been well studied; but the
reverse phenomenon of the stimulation of university research through the absorption of new
directions emanating from industry has yet to be investigated in much detail. We discuss the role
of federal funding of academic research in the microarray field, and the multiple pathways through
which federally supported development of commercial microarray technologies have transformed
core academic research fields.
Results and conclusion: Our study confirms the picture put forward by several scholars that the
open character of networked economies is what makes them truly innovative. In an open system
innovations emerge from the network. The emergence and diffusion of microarray technologies
we have traced here provides an excellent example of an open system of innovation in action.
Whether they originated in a startup company environment that operated like a think-tank, such
as Affymax, the research labs of a large firm, such as Agilent, or within a research university, the
inventors we have followed drew heavily on knowledge resources from all parts of the network in
bringing microarray platforms to light.
Federal funding for high-tech startups and new industrial development was important at several 
phases in the early history of microarrays, and federal funding of academic researchers using 
microarrays was fundamental to transforming the research agendas of several fields within 
academe. The typical story told about the role of federal funding emphasizes the spillovers from 
federally funded academic research to industry. Our study shows that the knowledge spillovers 
worked both ways, with federal funding of non-university research providing the impetus for 
reshaping the research agendas of several academic fields.
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Background
Since the work of Rosenberg and Kline[1], von Hippel[2],
Jaffe[3,4], Trajtenberg[5], and others, economists have
abandoned the linear model of innovation which pic-
tured a direct flow of innovation leading from scientific
discovery to product development, ending with market
introduction of new products. The linear model has been
replaced with a model that stresses the role of linkage,
feedback, and co-evolution among the various stages of
the innovation process from discovery through develop-
ment to commercialization, and features interdependen-
cies and learning across the various stages of the
innovation process. According to this picture, innovation
is a dynamic process drawing upon scientific and techni-
cal knowledge as well as from manufacturing experience,
and insights from business services that provide financ-
ing, marketing, regulatory, and commercial knowledge.
Despite the support for the network model of innovation,
there have been few (if any) examinations of the impact
of industry-based R&D or of the broader technological
infrastructure of a region on the research environment of
universities. Most examinations of the role of external
effects on the university research environment have
focused on the impact of defense department funding on
science and engineering research during the Cold War era,
or on the potential (almost entirely negative) effects of
corporate sponsorship of academic research programs in
biomedicine. The networked model of innovation
described above, however, posits relatively porous bound-
aries between firms and academic research programs as
one key element of an innovative region. The model sug-
gests a bi-directional flow of input between university and
industry innovation, in the form of licenses on inven-
tions, personnel, and tacit knowledge flowing from
(mostly federally funded) academic research programs, as
well as a flow from industry to the universities of new
technologies and research directions. Moreover, the
model suggests that these bi-directional flows should not
be considered as sequential; that is, originating in the uni-
versity environment and diffusing outward to stimulate
commercial innovations that subsequently reshape the
academic research environment. Rather, the model sug-
gests the possibility of mutual stimulation of research and
invention in both industry and academe, operating as a
positive feedback loop.
The flow of inventions into industry through the licensing
of university-based technologies has been well studied,
and our paper will contribute to that work; but the reverse
phenomenon of the stimulation of university research
through the absorption of new directions emanating from
industry has yet to be investigated in much detail. Our
study addresses this issue through the examination of the
sources of support, particularly federal support, and the
multiple pathways through which commercial microarray
technologies have transformed core academic research
fields. The first microarray system, the Affymetrix Gene-
Chip® originated beyond the walls of the academy, but
within a decade it made significant inroads into reshaping
the research environments of university programs as well
as launching a spectrum of competitive firms in several
industrial sectors within the Silicon Valley and other high
technology regions. Academic researchers collaborating
with Affymetrix scientists were quick to explore the power
of gene chips. They sought to improve upon and adapt
gene chips being supplied by firms such as Affymetrix to
their research questions. In addition, several academic
researchers connected with the Human Genome Initiative
actively pursued development of alternative types of DNA
microarrays, particularly spotted and ink-jet microarrays,
as competitor systems to the GeneChip®. While many of
the university-based microarray systems were assembled
in-house as home brew systems, several found their way
into industrial development. Since the mid-1990s the
lively – sometimes legally disputed – competition
between these platforms deemed essential for developing
a more systemic understanding of genetics has been
responsible for attracting hundreds of millions of dollars
into biotechnology and pharmaceutical companies. Fol-
lowing initial application in combinatorial synthesis of
organic materials, most spectacularly implemented as the
original Affymetrix GeneChip® in 1994, microarrays draw-
ing upon concepts of the original biochips were devel-
oped for combinatorial materials synthesis of inorganic
materials as well. By early 2000 the sky seemed to be the
limit for all branches of microarray technology.
The broad, significant impact and continuing rapid
enhancement of microarrays make the technology a suit-
able "probe" for tracking the various functions of different
types of institutions in the diffusion of an important tech-
nology. These institutions include the federal govern-
ment, universities and non-profit research institutions,
startups, established companies, and business services
such as legal firms and venture capital firms. We want to
understand the nature of institutional interactions in the
case of DNA chips and which relationships were particu-
larly crucial to advancing the technology as a major plat-
form in biomedical discovery. We will focus on the story
of microarrays from a variety of angles: we examine the
impetus for organizations or groups of researchers to
become involved with microarrays, the contextual factors
that enabled their participation, and how they applied
their existing expertise and collaborated with others to use
microarrays or build related systems. And finally, we trace
how these innovators' work contributed to changing the
overall landscape of research.Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Results and discussion
1. The invention of the GeneChip®
The microarray and gene chip grew out of efforts by a team
of scientists concerned with optimizing methods of drug
discovery. This group was assembled by Alex Zaffaroni,
the legendary CEO of Syntex and later founder of several
biotech firms, including Alza and DNAX. In 1988 Zaf-
faroni approached Lubert Stryer, professor of biochemis-
try at Stanford and inventor of numerous fluorescence-
tagging methods for enabling the Fluorescence Activated
Cell Sorter (FACS) as one of the primary tools of cell bio-
logical research, to become the chief scientific officer of
the new company Zaffaroni, J. Leighton Read, and Peter
Schultz [Note A] were founding called Affymax. The goal
of Affymax was to develop novel chemical approaches to
automated drug discovery. The traditional approach in
drug discovery had been to synthesize or discover new
candidate drugs and then test their activities one at a time.
This is a tedious, cumbersome, and increasingly expensive
approach, so speeding up or automating this process was
of substantial interest to pharmaceutical companies.
In building the company, Zaffaroni, Schultz, and Read did
not have a specific technology they intended to pursue.
However, feeling that recent developments in biotechnol-
ogy were about to render the problem of drug discovery
tractable, they assembled a star-studded scientific advisory
board from Stanford and several other universities [Note
B]. From the beginning the approach advocated by Avram
Goldstein of the Stanford Pharmacology Department
seemed most appealing. Goldstein urged the pursuit of
peptide synthesis as a means of generating chemical diver-
sity for identifying promising leads for drug molecules.
Goldstein argued that since receptors for any ligand can be
formed from short peptide sequences in the combining
sites of antibodies, it must be conversely true that from
short peptides, one could make a ligand for any receptor
[6]. Affymax could pursue the generation of large libraries
of small peptides with novel sequences against various
protein targets, analogous to the way in which the
immune system operates by mass screening its antibody
repertoire, identifying the ones that work best and making
more of those.
Several methods for generating large peptide libraries
through what was being called "combinatorial chemistry"
were coming on the scene in the mid-1980s. The field
actually got its start in 1963, when R. Bruce Merrifield
(Nobel Prize in chemistry, 1984) introduced the concept
of solid phase peptide synthesis (SPPS) whereby polypep-
tide chains as short as two amino acids (dipeptides) as
well as longer (protein) chains could be made in assem-
bly-line fashion using automated peptide synthesizers. In
the 1980s, Australian researcher Mario Geysen of the Uni-
versity of Melbourne (later at Glaxo Wellcome) showed
that SPPS could be the basis of multiple peptide synthesis.
Geysen's "peptide on a pin" method generated a variety of
short protein fragments by combining multiple amino
acids (the building blocks of peptides and proteins) in dif-
ferent permutations [7,8]. Each peptide was made on the
end of a pin-shaped polyethylene support, dipped into a
dish with a new amino acid for each step in the reaction.
By lining the pins in an array with the (originally 96) wells
of a microtitre plate dozens (even hundreds) of reactions
could be performed at the same time. Geysen's method
was the first example of a library of synthesized com-
pounds where the molecular identity could be known
based on the physical position of the compound in the
library [Note C].
Other candidate techniques for generating combinatorial
libraries of peptides were coming on the scene at about
the same time the Affymax board was developing its
approach [Note D]. But rather than pursuing any of these
options in developing combinatorial syntheses, Read and
Pirrung came up with a brilliant new approach of their
own which they called VLSIPS, for Very Large Scale Immo-
bilized Polymer Synthesis. In one of the meetings of the
Affymax scientific board, Leighton Read tossed out the
idea of just mimicking the makers of semiconductor
chips, who use beams of light to manipulate molecules on
solid surfaces in order to create random chemical diver-
sity. Though he had spent his career working with light
activation and fluorescent labeling, Stryer had not
thought of this possibility. Pirrung and Read got to work
on the idea and wrote up an invention record on VLSIPS,
modeling the name on the VLSI (very large scale integra-
tion) technology that was driving the semiconductor
industry at the time [Note E]. Read and Pirrung defined
the concepts and major parameters of light-directed syn-
thesis over the next few days, which they detailed in a pat-
ent application filed on June 7, 1989.
The next step for the group was to begin work on imple-
menting the idea of generating chemical diversity on an
array designed by a photolithographic process. Pirrung
was about to head off to Duke University to take up a new
professorship in biochemistry, so Stryer began inquiring
among local colleagues for the name of a young biochem-
ist who might be appropriate to head up the project of
producing a prototype and reducing the invention to prac-
tice. Stryer's long-time Berkeley collaborator Alexander
Glazer suggested Stephen Fodor, a young Princeton Ph.D.
with a NIH postdoctoral fellowship working on time-
resolved spectroscopy of bacterial and plant pigments in
his lab. Glazer recommended Fodor as a biochemist of
exceptional ability; indeed, he already had the reputation
of a visionary. Although taking a position in industry was
not of interest to Fodor, the opportunity to brainstorm
with Zaffaroni, Stryer, Berg, Schultz, Lederberg and DavisJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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was an opportunity he did not want to miss. The academic
appointment could follow. In July of 1989 Fodor joined
the group at the Affymax offices on Porter Drive in the
Stanford Industrial Park.
Over the next 18 months Fodor worked intensely with
Stryer in what both describe as the most stimulating and
productive period of scientific invention imaginable. The
invention they, together with their scientific colleagues at
Affymax, ultimately produced – light-directed spatially
addressable chemical synthesis – was quite literally the
marriage of biochemistry and the photolithography tech-
niques used in chip design in the local semiconductor
industry. What they demonstrated by 1991 in a now clas-
sic article published in Science was a process for depositing
onto a glass substrate – literally a microscope slide cover
in the first version of the invention – amino acid groups –
NH – that were blocked by a photolabile protecting chem-
ical group – X (Figure 1) [9]. Illumination with a laser
through a mask led to photodeprotection, allowing, in the
next step through chemical coupling, the addition of a
first chemical building block A containing a photolabile
protecting group X. In the next step, a different mask is
used to photoactivate a different region of the substrate. A
second labeled group B is then attached to the amino
groups exposed by the illumination through the mask.
This process is repeated as many times as desired to obtain
the desired set of products. By washing a bath of peptide
chains with a fluorescent marker attached to the end, it
was possible to determine the composition of amino
acids forming the chain with the aid of a photomultiplier/
scanner that operated similarly to the FACS (Fluorescence
Activated Cell Sorter). The initial microarray consisted of
1024 peptides in a 1.6 cm2 area generated in a ten-step
process. This was the first microarray designed specifically
for peptide synthesis, and at the same time Fodor devel-
oped a scanner for reading the output.
Part of the beauty of combining photolithography with
combinatorial chemistry is the resultant high density of
the compounds on the substrate. Theoretically, the only
physical limitation on the density is the degree to which
the compounds can be activated – in other words, the dif-
fraction of light. This provides for an incredibly high
degree of miniaturization, and in 1991, at the time of the
publication of the paper, Fodor and his colleagues at Affy-
max wrote:
Our present capability for high-contrast photodeprotec-
tion is better than 20 μm, which gives >250,000 synthesis
sites per square centimeter. There is no physical reason
why higher densities of synthesis sites cannot be achieved
[10].
Using photolithography essentially brought Moore's Law
to Affymax and to the new company Fodor launched
around it, Affymetrix. Similarly to the semiconductor
industry, Affymetrix has steadily increased the density of
synthesis sites, while making the chips more complex and
harder to manufacture [11]. Indeed, five years later,
Affymetrix had produced a prototype chip with a million
probes [12].
While work continued on peptide microarrays, Stryer and
the Affymax scientific board recognized a much more
immediate opportunity in the development of nucleic
acid microarrays. Solid phase synthesis of DNA is consid-
ered the most effective and reliable method of chemical
synthesis known. Given the strict base-pairing rules
(Watson-Crick pairing) obeyed by the four building
blocks of DNA (adenine, cytosine, guanine, and thymine,
or A, C, G, and T), a section of single-stranded DNA,
which might contain numerous genes and thus be used as
a probe, will match up only with its complementary
strand of DNA [cDNA for "complementary DNA"] to
form the double helix. RNA, which is DNA's chemical
cousin, also follows a strict base-pairing rule when bind-
ing to DNA, so the sequence of any RNA strand that pairs
up with DNA on a microarray can be inferred as well.
Combinatorial analysis based on light-directed synthesis
of DNA on a chip offered excellent opportunities, and
there were a number of reasons why Fodor wanted to pur-
sue DNA chips more vigorously than peptide arrays. Sim-
ply in terms of practical considerations of construction, a
peptide array of just two amino acid units for each
sequence with the 20 amino acids as building blocks pro-
duces an array of 400 sequences in 40 steps of the sort
described above. By contrast, in the same number of steps
(40), a DNA array of 10 unit (ATTGC...) sequences each
synthesized from the four nucleic acids as building blocks
can be constructed containing an array of one million
sequences. Moreover, DNA was ideally suited for light-
directed synthesis, and well-established techniques
existed for anchoring the DNA to a glass plate. Having
demonstrated that light-directed synthesis of peptides
using photolithographic masking technology was possi-
ble, and knowing that all the pieces for doing a parallel
DNA synthesis were within reach, Fodor was eager to shift
his attention entirely to developing the gene chip. In a fax
of May 15, 1990 to Stryer, Fodor outlined the reasons for
his convictions that it was time to devote full concentra-
tion on the gene chip. The upshot of this was to spin off
the gene chip project as its own company, Affymetrix (for
Affinity Matrix).
2. Drawing on the Silicon Valley Network
Fodor's prototype of the light-directed parallel peptide
synthesis array, the fluorescence scanner and computerJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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system for keeping track of each spot on the chip and
quantifying the ratio of tagged DNA matches as color spot
ratios in a computer graphic output, the photomasks and
appropriate photochemicals for constructing the arrays
were all designed in the heady "think tank" environment
of Affymax. The discussions in the Affymax scientific
board meetings allowed Fodor and his colleagues to draw
upon the knowledge and vision of some of the leading
academic biochemists and chemists of the day from sev-
eral universities, including Stanford, Berkeley, Cal Tech,
and Lawrence Livermore Labs. This back-and-forth flow of
information between academic researchers and the efforts
to launch the company had very much the style and spirit
of a Silicon Valley startup.
Concept of Light-Directed Spatially Addressable Parallel Chemical Synthesis Figure 1
Concept of Light-Directed Spatially Addressable Parallel Chemical Synthesis. Source: Fodor SPA, Stryer L, Read 
JL, Pirrung MC: USPTO 5,744,305. Arrays of Materials Attached to a Substrate, April 28, 1998, Sheet 1.Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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The distributed networked character of innovation in the
Silicon Valley is exemplified by Fodor's original prototype
system for using photolithography to design a peptide
microarray. As a way to construct chemical diversity,
Stryer suggested laying down a grid of parallel stripes –
each stripe with a different compound – one compound
at a time, then repeating the procedure with stripes laid
down perpendicularly on the grid, one at a time. In order
to see how to work it out using photolithography, Fodor
contacted Fabian Pease, professor of electrical engineering
at Stanford, specializing in electron beam lithographic
mask fabrication. Pease, a Ph.D. from Cambridge Univer-
sity, had been an assistant professor at UC Berkeley briefly
before moving, in 1967, to Bell Labs, where he first
worked on digital television and later led a group that
developed the processes for electron beam lithographic
mask manufacture and demonstrated a pioneering LSI cir-
cuit built with electron-beam lithography. Pease had been
at Stanford since 1978. Fodor and Stryer persuaded Pease
to join Affymax as a consultant on their project, and he
and Fodor spent a lot of time discussing technical aspects
of lithography needed to build the microarray. Pease took
Fodor around to various warehouses in Silicon Valley to
acquire old lithography instruments needed for building
the prototype peptide array. By May, 1990 with periodic
input from Pease, Fodor had a working semi-automated
lithography instrument that would do binary combinato-
rial peptide syntheses. Pease maintained his connection to
Fodor after the launch of Affymetrix in 1992. In 1993–94,
for instance, he took a sabbatical from Stanford to work
on the DNA microarray. Pease has been co-inventor along
with Fodor and Stryer on several key Affymetrix patents,
and he has continued to maintain a consulting relation-
ship with Affymetrix [Note F].
A similar story of Silicon Valley networking led to the
design of the first microarray scanner and reader. Through
the network of contacts of the Affymax scientific board,
Fodor got in touch with Peter Fiekowsky to assist him in
the development of a system for detecting and imaging
the fluorescently labeled markers of polymer sequences
on the peptide array. Fiekowsky had received his BS
degree in physics from MIT in 1977. Following gradua-
tion, he moved to Silicon Valley to work at NASA and
moved to Fairchild's artificial intelligence lab in 1983,
where he worked on image analysis in the semiconductor
industry. A year later, in 1984, Fiekowsky founded Auto-
mated Visual Inspection. The work he and Fodor did on
the array project led to two of the 23 patents Fiekowsky
holds in image-processing techniques ranging from semi-
conductor and flat panel inspection to medical x-rays and
gene chips [13,14].
James L. Winkler's involvement with Fodor and the core
technologies in the launch of Affymetrix provides another
typical example of the wide range of talents and the veri-
table gene pool of innovators who circulate through star-
tups in Silicon Valley. As Fodor recalled in an interview,
"Winkler was one of these guys who was just brilliant, did
not have any formal education, but could build anything.
He could take a blank circuit board and by the end of the
day have something he could plug into the back of the
computer to run an external piece of equipment." [Inter-
view with Stephen Fodor, August 2004] One of Winkler's
first contributions was the design and implementation of
the method and devices for flowing reagents through
block channels on the glass microarray substrate to form
the stripes of different peptides in combination with the
light-directed method of coupling and decoupling. After
each stripe was laid down, the substrate was shifted by a
rotating stage, and the process repeated to form arrays of
polymers on the substrate [14]. This was just the first of
what would become 31 patents on different aspects of
gene chip production and photolithographic mask
design, including a set of computer tools for selecting
probes and designing the layout of an array of DNA or
other polymers and using chip design files to design and/
or generate lithographic masks [16].
The guidance that Affymetrix received in its nascent years
from consultation arrangements with academics and
other local Silicon Valley experts was crucial to the
advance of gene chips and related systems. Research in
several domains had been going on for years in university
and government research projects that provided fertile
sources of ideas and techniques for developing the com-
plex technology of the DNA microarray. In fact, university
scientists appeared several dozen times on granted
Affymetrix patents, although some of these can be
accounted for by university faculty who had been hired
into the company [Note G]. In Table 1 we present the
results of our scan of the patent data for academic collab-
orations with Affymetrix [Note H].
We believe that these university collaborators provided
enabling expertise to Affymetrix, without these ongoing
consultations the development of the microarray would
have taken much longer. Federal funding has been partic-
ularly important in the development of microarrays. On
the one hand, as we have seen, federal funding for extra-
university-based industrial research and development
provided the capital to launch the cluster of innovative
technologies directly connected with the GeneChip® at
Affymetrix; and as we shall show in our case studies fur-
ther on, federal funding was crucial for the take off of
some competitor technologies in the microarray field. But
the work at Affymetrix and other firms in the microarray
field was heavily dependent on knowledge and expertise
that had accumulated in several academic disciplines,
including biochemistry, genetics, electrical engineering,Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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and computer science as a result of at least two decades of
federal funding from the NSF, NIH, DOE, and programs
such as the Human Genome Initiative, particularly at Bay
Area universities, Stanford, UC Berkeley, and UCSF. In
terms of the infrastructure of innovation discussed above
in our introduction, "knowledge spillovers" from these
federally supported academic research programs provided
important resources to the nascent field of microarrays.
Federal funding of extra-university research and develop-
ment by industry provided the stimulus for drawing those
resources into an accumulating ensemble of innovations
that gave rise to a major new technology and several new
lines of research. Government support, particularly to
nearby universities, lowered the cost of development
through the cultivation of experts who played a pivotal
role in the creation of the GeneChip®.
3. Federal funding of research and development
The development of combinatorial chemistry, microar-
rays, and the GeneChip® at Affymax and Affymetrix and
other Bay Area companies calls attention to an important
but often overlooked feature of the development of high
technology regions: namely, the role of federal funding
for research and development in companies that trans-
forms the academic research environment while launch-
ing new industrial sectors. Most discussions of federal
funding for research concentrate on the role of federal
funding in driving academic research. But as our analysis
of the rise of Affymetrix demonstrates, federal funding has
also been crucial in stimulating the other side of the equa-
tion in the symbiosis of Silicon Valley and research uni-
versities such as Stanford: namely, in the formation of the
startup companies and collaborations with large estab-
lished companies in the development of new innovative
technology. We frequently point to the massively central
role of the federal government in funding academic
research, but it is also the case that in Silicon Valley the
government has played and continues to play a large and
absolutely vital role in funding new industrial develop-
ment. This point has been made frequently about the role
of defense contracting in support of early developments in
the electronics and semiconductor industries during the
1950s–70s. But federal funding has also been a major fac-
tor in the development of biotech, materials science, and
several related industries from the 1990s to the present.
Table 2 and Figure 2  illustrate the significant contribution
of federal funding of both university and industry R&D in
California for the period of the 1990s to 2002.
Table 2: Federal Funding of R&D in California
Federal Funding of R&D in California
Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
R&D obligations (millions of dollars) 14,884 11,280 12,704 12,658 13,731 12,222 15,600 14,083 12,651 15,686
Industry R&D (millions of dollars) 26,541 28,541 28,710 28,710 34,011 35,568 39,047 45,769 41,745 39,664
Academic R&D (millions of dollars) 2,380 2,484 2,594 2,791 2,979 3,302 3,573 4,053 4,422 4,882
life sciences (percent) 58.00% 58.00% 57.00% 56.00% 56.00% 57.00% 56.00% 58.00% 58.00% 58.17%
engineering (percent) 13.00% 13.00% 13.00% 14.00% 15.00% 15.00% 15.00% 15.00% 13.00% 13.08%
physical sciences (percent) 13.00% 12.00% 12.00% 13.00% 13.00% 12.00% 12.00% 12.00% 11.00% 10.63%
Number of SBIR awards* 850 1,012 968 971 1,046 937 992 953 1,036 1,236
Utility patents issued to state residents 8,958 9,263 10,473 11,290 15,793 16,774 17,492 ND 18,598 18,829
Department of Defense (millions of dollars) 9,525 6,598 7,272 7,798 8,171 6,437 9,252 7,717 5,822 7,915
*In addition to SBIR and STTR awards, California firms received 184 ATP awards from 1990–2004
Table 1: Some of the University Faculty Appearing on Affymetrix Patents
Institution Collaborator Department – General Research Area
Stanford Stryer; Lubert School of Medicine – Biochemistry
Davis; Ronald W. School of Medicine – Biochemistry and Genetics
Pirrung; Michael C. Department of Chemistry – Organic Chemistry
Pease; R. Fabian Department of Electrical Engineering – Semiconductor Manufacturing
Quate; Calvin F. Department of Electrical Engineering – Nanomanufacturing
Princeton Levine; Arnold J. Department of Biochemistry – Oncology
University of California Mathales; Richard A. Department of Chemistry – Biophysical Chemistry
Schultz; Peter G. Department of Chemistry – Biochemistry
Argonne National Laboratory Mirzabekov; Andrei Biochip Technology Center – Molecular Biophysics
University of Michigan Collins; Francis S. Department of Internal Medicine – Human GeneticsJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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During the decade of the 1990s through the early 2000s
California ranked number one among states receiving fed-
eral funding for research. During this period the average
annual federal obligation to California R&D in industry
was approximately $6.96 billion, while support of univer-
sity-based R&D averaged approximately $3.3 billion.
Although the trend line points to a decreasing amount of
federal spending for industry R&D in the later years of the
period with an encouraging increase to universities, the
fact is that federal support of California R&D nearly tri-
pled support for university-based research. Of course, a
sizeable portion, typically exceeding 50% of the total Fed-
eral R&D in California is directed toward the defense
industries. But even allowing for defense spending and
not taking into consideration that some biotech research
is funded by the DOD, the amount of non-defense related
federal funding to industry in California exceeds federal
support for academic research by a considerable margin –
typically by a factor of two Particularly important for the
companies like Affymetrix, Symyx and other startups in
the microarray field we will discuss below is the number
of Small Business Innovation Research Program (SBIR)
awards and Small Business Technology Transfer Program
(STTR) awards going to California [Note I]. Throughout
this period California has averaged around 1,000 SBIR
and STTR awards, ranking first in both categories of
awards, with Massachusetts typically ranking second.
Moreover, during this period California has received 184
awards from the Advanced Technology Program, a pro-
gram that sponsors startup companies having a university-
based collaboration or academic PI. From the perspective
of Silicon Valley, the 1990s were the best of times. If we
compare all SBIR and STTR awards received by firms in the
Bay Area zip codes that constitute Silicon Valley versus all
California awards, the Bay Area has averaged 33 percent
(an average of $62 million per year) of the awards with a
Federal Funding for R&D to California Industrial Firms and to Universities (in millions of dollars) Figure 2
Federal Funding for R&D to California Industrial Firms and to Universities (in millions of dollars).Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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high of 39 percent in 1993 and a low of 25 percent in
2002. Several Bay Area companies, such as Affymetrix,
have been the recipients of multiple SBIR/STTR/ATP
awards. Figure 3 provides an overview of SBIR and STTR
awards specifically to the Bay Area.
When we consider that 58 percent of the federal funding
for R&D to universities in California has gone toward
funding innovation in the life sciences (see Table 2), the
importance of the NIH and the Human Genome Project
for the explosion of biotech firms in Silicon Valley
becomes evident. Federal funding has also been signifi-
cant in sustaining an entrepreneurial academic environ-
ment at Stanford and other Bay Area universities that have
participated in numerous waves of technological innova-
tion within the Silicon Valley through the students they
train and the faculty engaged in research and consulting as
well as in working with their university technology licens-
ing offices to disclose, patent, and license inventions. As
we have shown in another study, Stanford's openness to
(in former Stanford Dean of Engineering, Jim Gibbons'
phrase) "reverse engineering," the enhancement of new
research directions through absorption of technological
directions emerging in the Silicon Valley as key to its
entrepreneurial culture, is one of the pillars of its success.
Stanford receives approximately $500 million in federally
funded research grants annually. Berkeley and UCSF are
also in the top 20 research universities receiving federal
support. As we now see, federal funding is also deeply
involved in stimulating and sustaining the reverse engi-
neering essential to this co-evolution of Bay Area research
universities and the Silicon Valley.
Affymetrix was well positioned to take advantage of the
flows of information from both the academic and biotech
communities within Silicon Valley to acquire funding and
Small Business Innovation Research and Technology Awards to Silicon Valley Figure 3
Small Business Innovation Research and Technology Awards to Silicon Valley.Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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intellectual resources necessary for assembling the pool of
ideas, inventions, and know-how behind the microarray.
Local university help and federal funding were essential to
Affymetrix's push to begin developing the GeneChip® in
1990. Encouraged by Stryer and increasingly confident
about the success of the GeneChip®, Fodor sought to cap-
italize on the wave of funding for technologies associated
with the NIH's goal to uncover and exploit genetic infor-
mation. The Human Genome Project had been launched
a few months earlier and the NIH was soliciting proposals
for the development of technology in support of genom-
ics. Ron Davis from the Stanford Biochemistry Depart-
ment, together with David Botstein from Genetics, were
developing technology for the human genome sequenc-
ing effort at that time. Stryer invited Davis over to Affymax
to discuss the use of the gene chip technology to perform
genetic sequencing by hybridization. Paul Berg, who was
on the Affymax scientific board, was also interested in the
technology, and he attended the meeting. Both Davis and
Berg immediately saw the potential of the technology, and
Davis was excited enough about what he saw to propose a
collaboration with Fodor to apply for NIH funding to sup-
port the development of the gene chip. The NIH panel for
sequencing technology for the Human Genome Project
directed by Leroy Hood was meeting across the bay in
Walnut Creek, CA in the spring of 1991, and Paul Berg
arranged for Fodor to be invited to present on the peptide
and DNA chip project. James Watson and a blue ribbon
panel of genome scientists were in attendance, and when
the meeting concluded, Fodor and Davis were encouraged
to apply for funding. In September 1992 the first of sev-
eral grants to Affymetrix was awarded with Stephen Fodor
as PI. Co-PIs on the project were Ron Davis from Stanford
and Ronald Lipschutz from Daniel H. Wagner Associates,
a mathematics firm that contributed expertise on improv-
ing algorithms for sequence analysis [Note J]. The initial
NIH grant, funded from 1992–95, was for $2.5 million,
and together with a Phase I Small Business Innovation
Research (SBIR) grant from the Department of Energy
(one of several SBIR grants the company has received) for
$500,000 awarded in 1992, Fodor was able to demon-
strate proof of the concept of using large arrays of DNA
probes in genetic analysis. A Phase II grant was awarded to
assist Affymetrix in moving the technology towards com-
mercialization. Scientists at Affymetrix also received sev-
eral grants from the National Institutes of Health. For
example, Fodor was principal investigator on a second
round of NIH funding in 1995 for a three-year $5.5 mil-
lion NIH, grant from 1995–97. One component of this
grant addressed the development of chip-based sequenc-
ing, re-sequencing, sequence checking and physical,
genetic, and functional mapping. A technology develop-
ment component addressed the production of chips and
the development of instrumentation and software specific
to the chip applications.
Affymetrix's largest government award in the startup
phase of the company came from the Advanced Technol-
ogy Program (ATP) of the National Institute of Standards
and Technology (NIST) in the Tools for DNA Diagnostics
Focused Program competition in 1994. In its reports doc-
umenting the successes of its programs, the ATP lists
Affymetrix as one of its banner projects [17]. The ATP pro-
gram was started in 1990 to stimulate new science-based
research ventures and to encourage joint ventures among
universities, industry, research organizations, and consor-
tia of companies. A consortium established by Affymetrix
was awarded a $31.5 million, five-year grant in 1994 to
develop miniaturized DNA diagnostic systems. Under this
grant, Affymetrix directly received $21.5 million, some of
which was used to fund activities at a number of collabo-
rating institutions as subcontractors to the project. As part
of this grant, Affymetrix and its partner Molecular Dynam-
ics collaborated with researchers at the California Institute
of Technology, Lawrence Livermore National Laboratory,
Stanford University, the University of California at Berke-
ley, and the University of Washington to develop the next
generation of diagnostic devices to capitalize on the
advances of the Human Genome Project. After developing
its core chemical synthesis technology while still funded
under the ATP and SBIR grants, Affymetrix entered into
agreements with OncorMed to collaborate in develop-
ment of clinical validation of genetic testing services uti-
lizing the GeneChip® for analysis of genes associated with
cancer; and under a separate distribution and instrumen-
tation alliance between Affymetrix and Hewlett-Packard,
Hewlett-Packard began developing and supplying a next-
generation scanner to read the GeneChip® in 1996. The
Advanced Technology Program was particularly enthusi-
astic about the ways in which Affymetrix accelerated the
diffusion of its technology through alliances and collabo-
rations with the Genetics Institute, Roche Molecular Sys-
tems, Incyte Pharmaceuticals, and Glaxo Wellcome in
order to continue raising capital for expanding its own
internal R&D [18]. Table 3 tracks federal funding that
Affymetrix received over a ten year period [Note K].
Two themes emerge from the way the government funded
Affymetrix: the wide range of government organizations
that provided the funding, and the variety of federally
funded research projects at Affymetrix. The diversity of
agencies that saw benefits to the GeneChip® is quite appar-
ent: the Department of Energy, NASA, and several organi-
zations within the National Institutes of Health funded
Affymetrix over the eleven-year period studied. Later
affirmed by the breadth of research applications the DNA
chips found, this broad set of government health organi-
zations, such as the National Cancer Institute, the
National Institute of Allergy and Infectious Diseases, and





































































































































































Start End Total (in $K) Government Entity SBIR Brief Description
FG0392ER81275 137.5 Jul-92 May-95 550.0 Basic energy sciences (Dept. of Energy) Y SBIR phase I: develop spatially defined oligonucleotide arrays
R01HG000813 465.8 Sep-93 Aug-95 NA National Human Genome Research Institute N The long term goals of this proposal are to construct spatially 
defined arrays of oligonucleotide probes and to study the feasibility 
of using these arrays in applications of sequencing DNA by 
hybridization. A multidisciplinary research program is proposed 
which will integrate the necessary expertise in photolithography, 
photochemistry, synthetic chemistry, detection technology, 
informatics and applications to large scale DNA sequencing.
F32HG000105 20.3 Jun-93 Aug-96 NA National Human Genome Research Institute N NA
R43AI036809 37.5 Jul-94 Jan-95 75.0 National Institute of Allergy and Infectious Diseases Y Rapid detection of HIV drug resistance
70NANB5H103
1
5,246.3 Feb-95 Jan-00 31,478 Advanced Technology Program N Capillary-array electrophoresis, which separates and sizes DNA 
fragments, for use in a compact, reusable system for use with patient 
blood samples in labs and hospitals. Lawrence Livermore National 
Laboratory, Stanford University, the University of California 
(Berkeley), the California Institute of Technology, and the University 
of Washington also will work on the project.
R43CA067604 100.0 Mar-
95
Sep-95 100.0 National Cancer Institute Y Detection of mutations in human p53, msh2, mlh1 genes
R43DA010389 50.0 Sep-95 Mar-96 100.0 National Institute on Drug Abuse Y Typing human cytochrome p450 genes using DNA chips
A64472D 27.6 Jul-01 Jul-01 27.6 Human health and performance (NASA) N Studying the rat genome
P01HG001323 1,377.5 Sep-95 Aug-98 NA National Human Genome Research Institute N Human genome sequencing and mapping with dna probe arrays
R41CA075675 49.8 Jul-97 Sep-98 99.7 National Cancer Institute N Genotype for radiation sensitivity in cancer patients
R43AI040400 50.0 Sep-96 Mar-97 100.0 National Institute of Allergy and Infectious Diseases Y Chip based genotyping of mycobacterium drug resistance
R43CA081949 133.3 Jul-99 Sep-99 133.3 National Cancer Institute Y Reverese engineering biological signal transduction networks
R43HD038622 50.0 Sep-00 Aug-01 100.0 National Institute of Child Health and Human 
Development
Y Gene expression in endometriosis
R43HG001481 33.3 Apr-
96
Oct-97 33.3 National Human Genome Research Institute Y Mutation screening of the human mitochondrial genome
R43NS036491 50.0 Jul-97 Jan-98 100.0 National Institute of Neurological Disorders and 
Stroke
Y Cytokine message monitoring in oral tolerance
R44AI036809 250.0 Aug-
95
Jul-97 372.6 National Institute of Allergy and Infectious Diseases Y Rapid detection of HIV 1 drug resistance
R44CA067604 244.3 Mar-
96
Feb-98 359.3 National Cancer Institute Y Phase II of earlier project to develop a rapid and efficient method for 
detecting mutations on the human p53, msh2 and mlh1 genes
R44DA010389 163.9 Sep-96 Aug-98 205.5 National Institute on Drug Abuse Y Phase II of earlier project for typing human cytochrome p450 genes 
using DNA chips
R44DK053325 237.7 Jul-97 Sep-99 86.7 National Institute of Diabetes and Digestive and 
Kidney Diseases
Y Genomic responses to hormone signaling
R44HG001481 249.2 Jul-97 Aug-99 368.5 National Human Genome Research Institute Y Continuation of mutation screening of the human mitochondrial 
genome project
U01HG003147 661.0 Sep-03 Jul-05 985.5* National Human Genome Research Institute N Mapping sites of transcription and regulationJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Stroke, provided early testimony to the GeneChip®'s wide-
spread applicability.
These kinds of collaborative research efforts were a prereq-
uisite to acquiring federal funding to launch the company,
and they have continued ever since to be a deliberate core
strategy of Affymetrix, carried over from Affymax, to main-
tain simultaneously within the firm an entrepreneurial as
well as an academic environment. The firm's goal was to
attract preeminent researchers and convince them that the
company was creating cutting-edge technology. Steve
Fodor was persuaded to leave his postdoctoral research
position at UC Berkeley – despite his initial lack of interest
in leaving academia – by the possibility of continuing to
work with some the field's brightest academics as well as
having in-house funding to do research. The freedom to
seek outside grants to pursue research peripheral to the
company's core strategies was also considered an impor-
tant tool in attracting high-quality people to the project.
Affymetrix has been able to attract staff who continue to
keep their academic contacts through participation in
grant proposals, and who have the freedom to pursue
ideas to which they have dedicated their careers, while
gradually migrating to a commercial environment where
more tangible products can be generated. The exercise of
building a consortium of other companies to work
together under the ATP project, for example, fed a very
collegial environment where researchers worked hard
with the best people in their field around the world, push-
ing these technologies to a stage at which they could be
commercialized successfully.
4. The microarray revolution: diffusion of the GeneChip® 
and microarrays
The 1991 paper in Science on parallel chemical synthesis
using microarrays inaugurated the field of combinatorial
chemistry, and it may indeed be one of the key events in
the genomics revolution. By 1999 articles in Science
among many other scientific journals were celebrating the
widespread use of microarrays and the way they had trans-
formed genomics [19]. People who never thought they
would do large-scale gene studies suddenly were eager to
try their hand at monitoring thousands of genes at once.
The National Institutes of Health (NIH) heavily sup-
ported this trend, funding its own microarray studies and
providing grants to institutions to buy the technology.
This generous support of studies using microarrays gener-
ated a flood of data that traditional journals found hard to
accommodate and digital databases didn't yet know how
to handle. The NIH funded workshops to spread the tech-
nology. A Cold Spring Harbor Laboratory workshop on
microarrays led by Pat Brown from Stanford in 1999, for
instance, was the most over subscribed laboratory course
on record in the history of Cold Spring Harbor programs.
The new course was not even advertised, yet eight times as
many people signed up as could be accepted. Sixteen peo-
ple paid $1955 each to learn how to build and use a
machine for genetics research. For another $30,000, four
actually took the machine home.
Research and development of microarrays was the hot
new field in the 1990s. Although their approach was dis-
tinctive in focusing on in situ synthesis of DNA libraries on
a chip, Affymetrix was not alone in the microarray field.
About the same time the Affymetrix group was developing
the GeneChip®, several academic teams were developing
alternative microarray systems [Note L] [20]. Of particular
importance were spotted microarrays developed at Stan-
ford by Pat Brown, Dari Shalon, Stephen J. Smith, Mark
Schena and Ron Davis. The Stanford system was a contact
array that used two-color fluorescence hybridization. On
the heels of this system was a non-contact array developed
by Leroy Hood at Cal Tech that adapted the technology
for ink-jet printers to micro spot solutions of nucleotide
reagents printed on a glass substrate [21-23].
The spotted microarrays were extensions of methods that
had been in use in genome analysis and molecular biol-
ogy for two decades, going back to Edwin Southern's
introduction of the Southern Blot [24]. Another forerun-
ner for all the microarray work, including the work of
Fodor et al., were the methods for locating the position of
specific sequences in chromosomes through fluorescence
in situ hybridization (FISH), which allowed cell nuclei
and chromosomes to be fixed to glass microscope slides as
solid support. Ron Davis had contributed to those early
methods for identifying genes, and the same technique
was used to fix DNA to slides as solid support for his later
microarray work [25]. The technique of using ordered
arrays of DNA at the core of microarray techniques also
grew out of earlier work. Of special importance was the
dot-blot method introduced in 1979 by Fotis Kafatos, et
al., in which hybridizations were carried out in parallel
and fluorescent signals representing hybridization were
measured with an imaging method [26]. The procedures
for constructing these arrays were manual and the spots,
as in the Southern Blot method, were deposited on vari-
ous types of porous filters. While effective, these early
spotting methods on porous materials were not suitable
for the large-scale genome analyses that took off in the
1990s: it was not possible, for instance, to reduce the size
of the spots beyond certain limits, or to control their size
and shape on a porous membrane. The large scale auto-
mation of these dot-blot procedures was undertaken by
Hans Lehrach and his co-workers at the Berlin Max-
Planck-Institute for Molecular Biology in 1994. Lehrach's
group developed laboratory robotic systems for picking
and spotting clones onto filters [27]. This move toward
large-scale automation with robots coupled with the
replacement of the porous materials used in dot-blotsJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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with impermeable supports, such as glass or silicon, were
key steps in the development of the spotted microarray
systems. Non-porous surfaces permitted the use of very
small sample volumes and high sample concentrations of
spots. Over the next few years during the early 1990s tech-
nical advances made it possible to generate arrays with
very high densities of DNA spots, allowing for tens of
thousands of genes to be represented in areas smaller than
standard glass microscope slides. These changes to the
macroscopic format of filter based arrays resulted in the
miniaturized "biochip" format of the microarray that has
brought about a fundamental revolution in biological
analysis. By effectively making it possible to represent the
entire genome of an organism on a single biochip,
researchers are able to study the expression of all the genes
of a particular organism at once.
The spotted microarray developed in Pat Brown's lab con-
sisted of two principle pieces of hardware; the arrayer and
scanner [28]. The arrayer was a variation of the standard
"pick-and-place" XYZ-axis gantry robot common to many
large university molecular biology laboratories. Glass
slides coated with a poly-lysine surface were placed on a
platter. The robot picks up pre-synthesized single strand
or double stranded DNA samples from a 384 well micro-
titre plate by placing a specially designed cluster of spring-
loaded printing tips into adjacent wells of the source
plate, each tip filling with approximately 1 micro liter of
DNA solution. The DNA samples are, in most cases,
labeled by incorporating fluorescently tagged nucleotides.
The cone-shaped printing tips in Brown's original system
were stainless steel with manually sharpened points and a
slit up the center for holding the DNA solution. They
operated on the same principle as a quill pen; liquid was
drawn up by capillary action and deposited when the tip
made contact with the slide surface. The printing tips are
tapped leaving a small (less than 0.5 nano liters) drop at
identical positions on each slide. With the spacing
between tips deployed in the microarrayer the entire
human genome could be spotted onto a standard 1-inch
by 3-inch laboratory slide.
After hybridization a fluorescent image of the array is
acquired by a laser scanning confocal microscope. The
scanner has a laser (or lasers) producing light at the appro-
priate wavelength for the excitation spectra of the two
dyes (red and green) being used. The light passes through
the microscope objective and illuminates a single point
on the slide. The emitted light gathered by the objective is
filtered to remove the excitation beam, passed through a
pinhole (removing noise), and finally quantified in a
photomultiplier tube. The relative amount of fluorescence
is measured for each spot on the array using software
Brown's team developed for segmenting the images into
boxes and determining the average fluorescence for each
box. The advantage of using fluorescent signals is that they
do not disperse, and accordingly allow for very dense
array spacing. Also a significant advantage of using two or
more differently labeled probes targeted to the same spot
in this system is that each can be detected separately. In
this way, two-color hybridization detection allows for a
direct quantitative comparison of the abundance of spe-
cific sequences between two probe mixtures that are
hybridized competitively to a single array.
Brown, Shalon, and Smith [29], and Davis and Schena
[30] have argued that spotted microarrays have several
advantages over the in situ chips designed by Affymetrix
and Edwin Southerland. As we have seen in the case of
GeneChip® design, in situ synthesis methods work with
oligonucleotides, libraries of nucleic acid sequences of
between 2–25 base pairs. On a GeneChip® a given gene
might be represented by 15–20 different 25-mer oligonu-
cleotides that serve as unique sequence-specific detectors.
To be effective, the Affymetrix arrays require gene
sequence information for specifying the de novo synthesis
of the oligomers on the array. Spotted microarrays by con-
trast represent genes by single DNA fragments greater than
several hundred base pairs in length, and virtually any
length or origin. Moreover, spotted arrays do not require
prior sequence knowledge but can be produced from both
known and unknown cDNA and PCR fragments. Spotted
microarrays, it is argued, are more flexible and more easily
adaptable to a variety of research problems in genomics.
Also to the point, spotted microarrays are inexpensive by
comparison to Affymetrix chips [31]. Indeed, microarray-
ers based on the Brown-Shalon design could basically be
constructed in-house by most major university research
labs at a complete cost (in 1999) of around $60,000 [32].
Brown in fact has been so committed to the low cost pro-
duction of microarrayers and an open source approach as
a means to expedite the production of knowledge in
genomics that he posted on his Stanford website all the
details of manufacture for his microarray system, includ-
ing all the software updates for operation of the scanning
system, details on manufacturing and servicing the print-
ing tips, and other fine points of the system.
To study the adoption of both in situ and spotted micro-
array technologies, we considered the first academic arti-
cles either reporting studies based on using DNA chips or
simply discussing DNA microarrays. We focused on pre-
1999 studies because the DNA chip-based research began
to take off in 1999. These articles broke down into four
main types: results of microarray studies, overviews of
how to use gene chips, technology forecasts, and descrip-
tions of new or otherwise improved DNA chips. As an
indication of what types of studies were represented in the
early publications about gene microarrays, we present
Table 4.Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Of the early articles we studied, by far the majority
reported on the results of experiments using DNA chips.
Most of these studies aimed to uncover significant genetic
information in areas of existing interest, such as cancer
and cardiovascular disease; to understand the role of
genes already identified as being important to particular
diseases; or to attempt wide-scale gene expression moni-
toring of organisms whose genomes were already heavily
studied, such as the Arabidopsis plants and Saccharomy-
ces yeasts. By addressing several different research com-
munities, these initial studies served to broadcast the
potential of the new microarray technology. While these
studies were excellent advertisements for the technology,
they also opened up promising avenues of inquiry, help-
ing the technology establish itself in a variety of research
areas.
Getting involved with the technology early on was not
simply a matter of desire; generally, early authors had
some affiliation with Affymetrix. In part because of their
longstanding relationships and ongoing collaborations
with Affymetrix and due to their internal microarray
development efforts (largely arising from their collabora-
tion on the Human Genome Project), Stanford and the
NIH also possessed a great deal of in-house expertise in
using microarrays, which allowed them to assist research-
ers from other organizations in using the technology. In
fact, when we tabulated the affiliations of scientists
appearing on the pre-99 microarray studies, we found that
Stanford, NIH, and Affymetrix appeared most often. Table
5 lists the most frequently occurring author affiliations
within the set of 130 early articles on microarrays [Note
M]:
Perhaps unsurprisingly, the first organizations to publish
studies based on research using DNA chips were often
those that had the strongest links to gene chip manufac-
turers. In fact, the second most common organization to
appear as an author affiliation among the 130 studies we
surveyed published prior to 1999 was Affymetrix. The top
organization was Stanford, which had collaborated exten-
sively with Affymetrix in the development of the Gene-
Chip®, was developing its on pin-based arrayers, and
possessed a great deal of in-house expertise in using the
gene chips. The NIH's massive network of intramural
research and its strong links (including research collabo-
rations) to Stanford and Affymetrix made it third.
It was not simply a matter of being involved with the
development of various microarray systems that led to
publication, later research collaborations with and
between these expert organizations also coincided with
earlier and more frequent publication. For example, 28%
of articles with a Stanford author also had an Affymetrix
scientist and researchers from Stanford spin-out Synteni






Univ. Calif. Los Angeles 10
Synteni Inc. 8
Univ. Calif. Berkeley 5
Univ. Calif. San Diego 5
Roche 4
Duke University 3
Natl. Publ. Hlth. Institute, Finland 3
Tampere University, Finland 3
Univ. Calif. San Francisco 3
University of Pennsylvania 3
Table 4: Sample from Our Set of Pre-1999 DNA Chip Articles
Title Authors Publication
Towards Arabidopsis genome analysis: monitoring expression 
profiles of 1400 genes using cDNA microarrays
Ruan, Y; Gilmore, J; Conner, T PLANT JOURNAL
The integration of microarray information in the drug 
development process
Braxton, S; Bedilion, T CURRENT OPINION IN 
BIOTECHNOLOGY
Probing lymphocyte biology by genomic-scale gene expression 
analysis
Alizadeh, A; Eisen, M; Botstein, D; Brown, PO; 
Staudt, LM
JOURNAL OF CLINICAL 
IMMUNOLOGY
Microarrays: biotechnology's discovery platform for functional 
genomics
Schena, M; Heller, RA; Theriault, TP; Konrad, 
K; Lachenmeier, E; Davis, RW
TRENDS IN 
BIOTECHNOLOGY
Data management and analysis for gene expression arrays Ermolaeva, O; Rastogi, M; Pruitt, KD; Schuler, 
GD; Bittner, ML; Chen, YD; Simon, R; Meltzer, 
P; Trent, JM; Boguski, MS
NATURE GENETICS
Analysing genetic information with DNA arrays Case-Green, SC; Mir, KU; Pritchard, CE; 
Southern, EM
CURRENT OPINION IN 
CHEMICAL BIOLOGY
From expressed sequence tags to 'epigenomics': An understanding 
of disease processes
Zweiger, G; Scott, RW CURRENT OPINION IN 
BIOTECHNOLOGY
Detection of heterozygous mutations in BRCA1 using high density 
oligonucleotide arrays and two-colour fluorescence analysis
Hacia, JG; Brody, LC; Chee, MS; Fodor, SPA; 
Collins, FS
NATURE GENETICSJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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(whose technology was largely based on the Dari Shalon
and Pat Brown system) appeared on 20% of the Stanford
publications.
The top three organizations listed above – Stanford,
Affymetrix, and the NIH – were the major "hubs" (or
highly connected points) in co-authorship networks for
the 130 studies we surveyed. To study the network of col-
laborations during this early phase of research using gene
chips, we used an analysis tool that graphically places
organizations according to their co-authorships with
other organizations [Note N]. For example, in Figure 4,
Affymetrix (large green node) co-authored with Prince-
ton, but Princeton did not co-author with NIH (large blue
node), so Princeton is near Affymetrix but distant from
NIH. Furthermore, although Affymetrix and NIH co-
authored papers together, they also co-authored papers
with several organizations that did not co-author with
both organizations, thus Affymetrix and NIH are pulled
some distance apart (as opposed to NIH and Stanford, the
large red node, which share more institutional co-
authors) [Note O].
There were many organizations represented in the first
130 articles dealing with DNA microarrays, but Stanford,
Affymetrix, and the NIH emerge as major nodes in this
network. Often, other organizations would partner with
one or more of these major players and then go on to col-
laborate with organizations previously outside the net-
work. The heavy overlap of collaborations indicates that
this was a fairly tight-knit research community. Several
organizations in the center and upper right of the map col-
laborated with at least two of the three major players.
Interestingly, many of the initial participants in micro-
array based research were also involved in the Human
Genome Project.
Institutions that were the first to publish microarray stud-
ies and that collaborated with DNA microarray makers
were also the best able to attract federal funding for micro-
array based research [Note P]. Organizations that
appeared in Table 5 as having been the first to publish
studies based on gene chip research tended to be those
that received the most federal grants for DNA microarray
research over the period 1993–2004 (shown in Table 6)
Organizational Co-Authorships from First 130 DNA Microarray Articles Figure 4
Organizational Co-Authorships from First 130 DNA Microarray Articles.Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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[Note Q]. This particular phenomenon in the academic
setting of being first to collaborate with Affymetrix, subse-
quently being first to publish DNA microarray based stud-
ies, and in turn receiving more federal funding is roughly
analogous to the type of positive feedback loop that econ-
omists have used to describe how initially successful high
technology firms become increasingly entrenched within
their industries.
DNA microarray makers such as Affymetrix have been
hubs for an expanding network of companies and tech-
nologies across the spectrum of technologies fueling con-
temporary biotech, gene-based medical therapies, and
areas of materials science. These companies have drawn
heavily upon academic researchers as consultants and sci-
entific advisory board members, and they have collabo-
rated with academic researchers in sponsoring
postdoctoral work and a variety of research projects
funded by the NIH, NSF, DOE, and other federal agencies.
The academic researchers involved have only in rare cases
relinquished their university positions to move into
industry. While some of these individuals, such as
Schultz, Berg, Stryer, Ron Davis, Mark Davis, and others
have been involved in numerous startups, they have
returned to their universities (Stanford and UC Berkeley)
where they have continued to develop graduate programs
that incorporate these new innovations. Other Stanford
faculty, such as Fabian Pease and Calvin Quate, have con-
tinued as advisors and collaborators in shaping new gen-
erations of microarray and sequencing technologies at
Affymetrix. Through these technologies and the academic
researchers who have participated in developing them,
research programs at Stanford and other universities in a
variety of different disciplines have taken new shape and
direction.
In order to trace the widespread impact of microarrays on
the academic research environment, Table 7 presents a
chronological overview of the interest in microarrays and
gene chips by several disciplines as indicated by citations
to the first 130 articles published based on microarray
research. (For the totals from nearly all fields citing micro-
array research, see Appendix A) [Note R]. The data show
that interest in DNA chips and microarrays more generally
was manifest in a variety of disciplines. As a new, promis-
ing, but unstable and unproven technology, microarrays
were attractive as a platform that could be improved upon
by many different fields. In an era when researchers were
motivated to find new ways to interpret the massive
amounts of data being generated by the Human Genome
Initiative, researchers in just about every field of biomed-
icine were looking for novel high-throughput techniques
to refine genetic analysis and develop tools for rapidly
interpreting gene expression data. In many of the new
areas, the microarray and gene chip were tools for advanc-
ing a program of "molecularizing" established disciplines.
But this could not be accomplished by simply plugging in
a microarray and reading off the results. New tools and
even modifications of the gene chip itself had to be devel-
oped in order to assimilate the microarray to the research
objectives of these several fields. Multidisciplinary teams
of researchers and collaboration between academic
researchers and their industry partners proved essential to
advancing the technology. The demand for alternatives
greatly expanded the market for these research tools and,
as we show below, created opportunities for other firms to
enter the market.
The top three categories citing these studies (Biochemis-
try, Biotechnology, and Genetics) were not surprising;
they represented the areas DNA microarrays were squarely
targeted to address. However, the amount of interest gen-
erated around microarray research methods was quite
striking. When first released there was much concern
regarding the reliability of the chips, quality control issues
in manufacturing them, and how to interpret results of
microarray experiments. In some cases it was difficult to
reproduce the results of experiments based on DNA chips.
In addition, researchers discovered that each manufac-
turer's DNA microarray had its relative strengths and
weaknesses; finding the right chip for the job was and still
is of significant concern. Many studies were done both to
address a particular research question and to learn some-
thing about how to better use gene chips.
Table 6: Organizations Receiving the Most Federal Grants for 
Research Using Microarrays (1993–2004)
Organization Grants
NIH (Intramural Grants) 108
UNIVERSITY OF CALIFORNIA 80
STANFORD UNIVERSITY 43
UNIVERSITY OF TEXAS 29
UNIVERSITY OF WASHINGTON 18
DUKE UNIVERSITY 17
UNIVERSITY OF ILLINOIS 17
UNIVERSITY OF WISCONSIN 17
EMORY UNIVERSITY 16
UNIVERSITY OF ALABAMA 16
UNIVERSITY OF MICHIGAN 16
UNIVERSITY OF PENNSYLVANIA 16
WASHINGTON UNIVERSITY 16
UNIVERSITY OF COLORADO 15
BAYLOR COLLEGE OF MEDICINE 14
JOHNS HOPKINS UNIVERSITY 14
SCRIPPS RESEARCH INSTITUTE 14
UNIVERSITY OF ARIZONA 13

































































































































































Table 7: Fields Citing Early Microarray Studies Over Time
Field of Study 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Total N
Biochem. Research Methods 0.1% 0.3% 0.2% 0.1% 0.2% 0.9% 2.3% 4.6% 7.4% 12.1% 11.8% 16.7% 15.6% 14.0% 13.8% 100.0% 1990
Biochem. & Mol. Biology 0.0% 0.3% 0.2% 0.3% 0.3% 0.7% 2.2% 5.5% 11.8% 12.9% 14.8% 14.9% 13.6% 12.4% 10.1% 100.0% 4457
Biophysics 0.0% 0.3% 0.0% 0.3% 1.0% 0.7% 2.0% 6.0% 11.5% 11.9% 13.3% 12.4% 13.0% 12.5% 15.1% 100.0% 615
Biotech. & Appl. Microbio. 0.1% 0.2% 0.1% 0.3% 0.2% 1.0% 2.0% 6.3% 10.1% 12.7% 11.4% 14.0% 15.0% 14.5% 12.1% 100.0% 2882
Chemistry, Analytical 0.0% 0.2% 0.1% 0.1% 0.3% 1.0% 2.7% 4.6% 15.8% 14.0% 12.1% 18.0% 8.6% 12.2% 10.3% 100.0% 920
Chemistry, Physical 0.0% 0.5% 0.5% 0.5% 1.4% 1.4% 2.3% 5.6% 4.2% 11.1% 5.1% 14.4% 18.5% 19.0% 15.7% 100.0% 216
Clinical Neurology 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.7% 3.4% 9.3% 13.6% 14.4% 16.9% 17.8% 13.6% 9.3% 100.0% 118
Eng., Electrical & Electronic 0.0% 0.0% 0.9% 0.0% 0.0% 0.9% 0.0% 2.8% 1.9% 6.5% 0.9% 16.8% 23.4% 28.0% 17.8% 100.0% 107
Environmental Sciences 0.0% 0.0% 0.0% 0.0% 0.8% 0.0% 0.0% 3.9% 5.4% 4.7% 22.5% 19.4% 14.7% 18.6% 10.1% 100.0% 129
Genetics & Heredity 0.0% 0.2% 0.1% 0.1% 0.0% 0.9% 3.1% 5.5% 14.6% 13.7% 13.3% 13.8% 12.7% 12.3% 9.7% 100.0% 2504
Hematology 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.8% 1.9% 7.0% 13.6% 14.9% 18.4% 14.4% 14.6% 14.1% 100.0% 369
Immunology 0.0% 0.3% 0.0% 0.2% 0.0% 0.3% 1.5% 7.6% 4.7% 16.8% 16.0% 11.8% 14.7% 13.9% 12.3% 100.0% 619
Medical Lab Tech. 0.3% 0.3% 0.3% 0.3% 0.3% 0.6% 4.3% 8.4% 13.8% 17.9% 11.5% 13.5% 8.4% 10.7% 9.5% 100.0% 347
Medicine, General & Internal 0.0% 0.0% 1.0% 0.0% 0.0% 0.0% 4.5% 3.5% 20.3% 10.9% 13.9% 13.9% 12.9% 11.9% 7.4% 100.0% 202
Medicine, Res. & Exper. 0.0% 0.2% 0.2% 0.0% 0.2% 0.4% 5.6% 5.6% 14.7% 13.2% 18.0% 9.3% 12.2% 8.7% 11.8% 100.0% 551
Microbiology 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 1.6% 4.8% 9.4% 14.2% 17.5% 12.2% 14.3% 15.2% 10.6% 100.0% 755
Neurosciences 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 0.9% 4.9% 5.6% 12.8% 23.2% 21.1% 6.0% 16.0% 9.0% 100.0% 431
Oncology 0.0% 0.0% 0.1% 0.0% 0.0% 0.1% 1.0% 2.3% 7.1% 9.2% 14.5% 17.7% 16.7% 17.0% 14.5% 100.0% 1813
Pathology 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 1.2% 7.3% 6.4% 16.9% 15.0% 20.2% 18.1% 14.9% 100.0% 753
Peripheral Vascular Disease 0.0% 0.0% 0.0% 0.0% 0.9% 0.0% 1.9% 3.7% 14.0% 23.4% 10.3% 18.7% 9.3% 7.5% 10.3% 100.0% 107
Pharmacology & Pharmacy 0.0% 0.0% 0.5% 0.8% 0.8% 0.8% 3.2% 4.1% 5.0% 16.8% 18.3% 13.0% 13.0% 14.5% 9.5% 100.0% 662
Physics, Applied 1.1% 1.1% 1.1% 1.1% 1.1% 2.3% 0.0% 4.5% 2.3% 3.4% 6.8% 12.5% 22.7% 20.5% 19.3% 100.0% 88
Physiology 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.8% 1.2% 6.1% 13.4% 18.3% 18.7% 17.5% 13.0% 10.6% 100.0% 246
Plant Sciences 0.0% 0.0% 0.0% 0.0% 0.2% 0.2% 0.2% 5.5% 7.5% 10.1% 16.4% 20.9% 14.8% 11.0% 13.3% 100.0% 602
Psychiatry 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 3.3% 20.0% 10.0% 22.2% 12.2% 4.4% 5.6% 11.1% 11.1% 100.0% 180
Public, Env. & Occup. Health 0.0% 0.0% 0.0% 0.0% 0.8% 0.8% 1.5% 2.3% 6.1% 4.6% 20.6% 22.9% 13.7% 13.7% 13.0% 100.0% 262
Statistics & Probability 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.9% 1.5% 7.7% 9.9% 22.4% 21.3% 17.9% 18.1% 100.0% 648
Surgery 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.4% 2.4% 4.3% 16.1% 15.2% 21.3% 21.3% 17.1% 100.0% 211
Toxicology 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.0% 3.1% 5.8% 19.4% 14.3% 18.2% 14.7% 11.6% 12.4% 100.0% 258
Computer Science 0.0% 0.0% 0.0% 0.3% 0.0% 0.3% 0.0% 0.9% 2.0% 7.9% 10.5% 19.2% 21.0% 19.2% 18.6% 100.0% 656
Materials Science 0.0% 0.8% 0.8% 0.0% 2.3% 1.5% 2.3% 4.6% 8.5% 6.2% 10.0% 12.3% 13.8% 15.4% 21.5% 100.0% 130
Mathematics 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.8% 1.7% 7.9% 10.1% 23.6% 21.0% 16.5% 18.0% 100.0% 605
N per year 6 40 35 42 51 146 462 1135 2285 2973 3386 3830 3585 3447 3010Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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The next major adopters of microarrays were those inves-
tigating cancer and cell biology. Often, these studies
involved comparing the expression of thousands of genes
in tumor cells to their expression in non-tumor cells. The
same type of cancer (e.g. breast cancer) may involve a dif-
ferent (and very large) set of genes depending on the
patient, so it is not enough to simply determine that gene
A is related to cancer B. It is often necessary to capture the
broad set of involved genes (including those regulating
expression) and their interplay to begin to profile particu-
lar cancers. An understanding of the processes in cancer-
ous cells aids in designing future drugs to disrupt the
chain of events. More immediately, gene expression pro-
filing of a particular patient's tumor through diagnostics,
the genes for which are often selected by expression anal-
ysis with high density microarrays, enables prediction of
the efficacy of existing treatments. Thus, microarrays ena-
bled comparative study of gene expression in cells that led
to insights about the complex processes behind cancer
progression, but they also allowed for research on select-
ing patient-specific treatments based on gene expression
profiles in tumor cells.
Some of the biological and medical fields affected by
microarray research raise equally interesting issues. Micro-
arrays enabled a broad range of researchers to better
address questions such as how certain genes and their
expression are related to the processes involved in partic-
ular diseases, to development and aging, and to the work-
ings of the brain. Microarrays could also be used to
address questions on evolution. In other words, microar-
rays not only provided a valuable tool to these researchers;
in certain cases, they made genetics more relevant to their
respective fields than it had been previously, and in partic-
ular, to their methods of inquiry.
There were also technical fields that took up research on
DNA microarrays not for purposes of applying them
within the field but in order to improve them and to pro-
vide better methods for interpreting gene expression data.
Physicists, chemists and various kinds of engineers created
custom microarrays, labeling systems for genetic material
and systems for reading gene chips, or they explored new
methods of manufacturing arrays. Interestingly, the sheer
volume of data generated by gene expression studies
forced geneticists, biologists, and others using microarrays
to pull statisticians, mathematicians, and computer scien-
tists into their research teams. Methods of reading, visual-
izing, and interpreting gene expression information and
linking it to existing scientific knowledge became codified
in a plethora of computer programs from in-house statis-
tics and visualization tools at universities to major soft-
ware suites developed by corporations that can be
connected to online repositories of biological informa-
tion.
In order to convey a sense of the interests in microarray
technologies motivating researchers, we present in Table 8
a list of articles from many of the new fields that received
a substantial number of citations. Many of these articles
served as a basic bridge into a new discipline, making
microarrays relevant to the science and/or vice versa. In a
network view, they would represent a major forward-link-
ing hub that collapses a question addressed within the
authors' traditional field of study into a problem solvable
with microarrays and motivates a flurry of subsequent
research in that new domain. For example, statistical anal-
ysis of gene expression data has become a major topic of
research at many universities; as the table shows, one
study that used statistical methods to evaluate microarray
data, despite being published in 2000, was cited over 300
times.
While some of these articles' citations simply reflect
acknowledgement of the new technology being applied in
some fashion, many aim at expanding the capabilities of
microarray technologies by addressing fundamental ques-
tions in an existing research domain. Nonetheless, both
types of citations indicate the growing relevance of gene
expression and other microarray based studies on various
scientific fields.
Below we chart the rising use of microarray technologies
and research underpinned by microarrays through counts
of microarray related studies [Note S] by subject (accord-
ing to the Scopus database) and by departmental affilia-
tion of at least one of the authors. We are particularly
interested in highlighting the growth of use in particular
disciplines in addition to biology, biochemistry, and
genetics, and in illustrating how microarrays became rele-
vant to a host of fields that could benefit from a better
understanding of gene processes. In addition, we try to
demonstrate that non-biological fields such as computer
science became involved in order to enhance the micro-
array research itself. While neither subject classifications
nor departmental affiliations provide a definitive account
of the story of microarrays in these fields, we believe that
the two approaches to tracking diffusion reinforce one
another and at a minimum point to the growing relevance
of large scale gene expression monitoring technologies in
various academic disciplines. Figure 5 presents the
number of microarray articles by subject over a seven year
period in order to demonstrate the growing relevance of
microarrays to diverse disciplines. Following, Figure 6
attempts to capture a similar picture of the spread of
microarrays into different corners of academia through
the departmental affiliations of authors rather than the
subject classification of the article as in Figure 5.
As we have discussed above, microarrays were not a sim-
































































































































































Table 8: Articles Indicating the Relevance of DNA Chips to Various Disciplines
Field of Study Authors Article Title Year Cited
Biochemistry & Molecular Biology Mathews, DH; Sabina, J; Zuker, M; Turner, DH Expanded sequence dependence of thermodynamic parameters 
improves prediction of RNA secondary structure
1999 1123
Biophysics Cosnier, S Biomolecule immobilization on electrode surfaces by entrapment or 
attachment to electrochemically polymerized films. A review
1999 188
Biotechnology & Applied Microbiology Lockhart, DJ; Dong, HL; Byrne, MC; Follettie, MT; Gallo, MV; Chee, MS; 
Mittmann, M; Wang, CW; Kobayashi, M; Horton, H; Brown, EL
Expression monitoring by hybridization to high-density oligonucleotide 
arrays
1996 1556
Cardiac & Cardiovascular Systems Stanton, LW; Garrard, LJ; Damm, D; Garrick, BL; Lam, A; Kapoun, AM; 
Zheng, Q; Protter, AA; Schreiner, GF; White, RT
Altered patterns of gene expression in response to myocardial infarction 2000 130
Cell Biology Spellman, PT; Sherlock, G; Zhang, MQ; Iyer, VR; Anders, K; Eisen, MB; 
Brown, PO; Botstein, D; Futcher, B
Comprehensive identification of cell cycle-regulated genes of the yeast 
Saccharomyces cerevisiae by microarray hybridization
1998 1110
Chemistry, Medicinal GALLOP, MA; BARRETT, RW; DOWER, WJ; FODOR, SPA; 
GORDON, EM
APPLICATIONS OF COMBINATORIAL TECHNOLOGIES TO DRUG 
DISCOVERY
1994 927
Chemistry, Physical Collier, CP; Vossmeyer, T; Heath, JR Nanocrystal superlattices 1998 231
Clinical Neurology Whitney, LW; Becker, KG; Tresser, NJ; Caballero-Ramos, CI; Munson, 
PJ; Prabhu, VV; Trent, JM; McFarland, HF; Biddison, WE
Analysis of gene expression in multiple sclerosis lesions using cDNA 
microarrays
1999 122
Computer Science Furey, TS; Cristianini, N; Duffy, N; Bednarski, DW; Schummer, M; 
Haussler, D
Support vector machine classification and validation of cancer tissue 
samples using microarray expression data
2000 237
Endocrinology & Metabolism Kao, LC; Tulac, S; Lobo, S; Imani, B; Yang, JP; Germeyer, A; Osteen, K; 
Taylor, RN; Lessey, BA; Giudice, LC
Global gene profiling in human endometrium during the window of 
implantation
2002 106
Genetics & Heredity Ashburner, M; Ball, CA; Blake, JA; Botstein, D; Butler, H; Cherry, JM; 
Davis, AP; Dolinski, K; Dwight, SS; Eppig, JT; Harris, MA; Hill, DP; Issel-
Tarver, L; Kasarskis, A; Lewis, S; Matese, JC; Richardson, JE; Ringwald, M; 
Rubin, GM; Sherlock, G
Gene Ontology: tool for the unification of biology 2000 1273
Hematology Melnick, A; Licht, JD Deconstructing a disease: RAR alpha, its fusion partners, and their roles 
in the pathogenesis of acute promyelocytic leukemia
1999 370
Immunology Klein, U; Tu, YH; Stolovitzky, GA; Mattioli, M; Cattoretti, G; Husson, H; 
Freedman, A; Inghirami, G; Cro, L; Baldini, L; Neri, AN; Califano, A; 
Dalla-Favera, R
Gene expression profiling of B cell chronic lymphocytic leukemia reveals 
a homogeneous phenotype related to memory B cells
2001 197
Infectious Diseases Nijhuis, M; Schuurman, R; de Jong, D; Erickson, J; Gustchina, E; Albert, J; 
Schipper, P; Gulnik, S; Boucher, CAB
Increased fitness of drug resistant HIV-1 protease as a result of 

































































































































































Materials Science, Biomaterials Kane, RS; Takayama, S; Ostuni, E; Ingber, DE; Whitesides, GM Patterning proteins and cells using soft lithography 1999 262
Materials Science, Multidisciplinary Nakagawa, M; Oh, SK; Ichimura, K Photopatterning and visualization of adsorbed monolayers of bis(1-
benzyl-4-pyridinio)ethylene moieties
2000 255
Medicine, General & Internal Ross, R Mechanisms of disease – Atherosclerosis – An inflammatory disease 1999 5009
Medicine, Research & Experimental Kononen, J; Bubendorf, L; Kallioniemi, A; Barlund, M; Schraml, P; 
Leighton, S; Torhorst, J; Mihatsch, MJ; Sauter, G; Kallioniemi, OP
Tissue microarrays for high-throughput molecular profiling of tumor 
specimens
1998 916
Mycology Goldstein, AL; McCusker, JH Three new dominant drug resistance cassettes for gene disruption in 
Saccharomyces cerevisiae
1999 188
Neurosciences Mirnics, K; Middleton, FA; Marquez, A; Lewis, DA; Levitt, P Molecular characterization of schizophrenia viewed by microarray 
analysis of gene expression in prefrontal cortex
2000 243
Oncology SolinasToldo, S; Lampel, S; Stilgenbauer, S; Nickolenko, J; Benner, A; 
Dohner, H; Cremer, T; Lichter, P
Matrix-based comparative genomic hybridization: Biochips to screen for 
genomic imbalances
1997 259
Pathology Knuutila, S; Bjorkqvist, AM; Autio, K; Tarkkanen, M; Wolf, M; Monni, O; 
Szymanska, J; Larramendy, ML; Tapper, J; Pere, H; El-Rifai, W; Hemmer, 
S; Wasenius, VM; Vidgren, V; Zhu, Y
DNA copy number amplifications in human neoplasms – Review of 
comparative genomic hybridization studies
1998 339
Peripheral Vascular Disease Hwang, DM; Dempsey, AA; Wang, RX; Rezvani, M; Barrans, JD; Dai, KS; 
Wang, HY; Ma, H; Cukerman, E; Liu, YQ; Gu, JR; Zhang, JH; Tsui, SKW; 
Waye, MMY; Fung, KP; Lee, CY; Liew, CC
A genome-based resource for molecular cardiovascular medicine – 
Toward a compendium of cardiovascular genes
1997 110
Pharmacology & Pharmacy DOOLEY, CT; HOUGHTEN, RA THE USE OF POSITIONAL SCANNING SYNTHETIC PEPTIDE 
COMBINATORIAL LIBRARIES FOR THE RAPID-DETERMINATION 
OF OPIOID RECEPTOR LIGANDS
1993 118
Plant Sciences Reymond, P; Weber, H; Damond, M; Farmer, EE Differential gene expression in response to mechanical wounding and 
insect feeding in Arabidopsis
2000 305
Spectroscopy Yates, JR Mass spectrometry and the age of the proteome 1998 351
Statistics & Probability Kerr, MK; Martin, M; Churchill, GA Analysis of variance for gene expression microarray data 2000 326
Toxicology Waring, JF; Ciurlionis, R; Jolly, RA; Heindel, M; Ulrich, RG Microarray analysis of hepatotoxins in vitro reveals a correlation 
between gene expression profiles and mechanisms of toxicity
2001 107
Virology Martinez-Picado, J; Savara, LV; Sutton, L; D'Aquila, RT Replicative fitness of protease inhibitor-resistant mutants of human 
immunodeficiency virus type 1
1999 182
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understanding the role of particular genes. They often had
to enlist the support of colleagues in other departments to
analyze, view, and interpret the data provided by DNA
microarrays. In addition, research to improve numerous
aspects of gene chip experiments took hold in depart-
ments outside of the biological sciences. In addition, bio-
logical fields that still had to profit significantly from the
results of mapping the human genome and myriad stud-
ies on individual genes were now able to better link exist-
ing research questions to genomics questions.
5. Commercial interest in DNA microarray technology
Although Affymetrix has dominated the commercial mar-
ket for DNA microarrays since its inception, distantly fol-
lowed by Agilent, it is important to note that nearly half
of scientists using microarray systems had built them
locally according to plans similar to those made available
by Pat Brown and his colleagues at Stanford. While these
generally offered less reliability, consistency, and had
fewer applications, they were far cheaper than the com-
mercially available systems.
Alongside the research universities and other non-profit
institutions that had begun in incorporating gene chips
into their research programs, many companies were look-
ing at how to enter the gene chip business and how to
build complementary systems. Interestingly, many of
these efforts, particularly at the smaller companies were
offshoots of the university research that had begun earlier
on some aspect of gene chip applications or technologies,
such as bioinformatics software. Larger companies often
stepped in by applying existing expertise and familiar
manufacturing techniques to building their own versions
of DNA microarrays.
In Table 9 we have identified organizations with a com-
mercial interest in gene chips through their patents' back-
ward citations to Affymetrix patents [Note U]. After
finding the organizations that cited Affymetrix patents
most frequently (reflecting their interest in microarray
technologies), we selected those that we believed repre-
sented one of the common or important directions that
microarray technologies took following the introduction
Number of Microarray Articles by Subject (1998–2004) Figure 5
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of the GeneChip® [Note T]. In the rightmost column we
indicate whether the organization received any types of
government grants for its research in this area. Twenty-five
of the forty organizations listed received government
grants (note the presence of universities, which depend
heavily on government funding for all their research, and
large companies, which rarely receive funding for this type
of research). In the case of smaller, recently formed com-
panies, 20 out of 28 received government funding. While
the data is limited, it appears that new companies build-
ing technologies around microarrays were heavily sup-
ported by the federal government, helping to broaden the
applications and power of the technology.
6. Case studies
Our case studies were chosen to explore different perspec-
tives on the issues we have defined as salient features of
the networked, symbiotic structure supporting innovation
in technology regions such as the Silicon Valley; namely,
the role of federal support, the ability of companies to
draw upon universities to provide expertise in addressing
challenging scientific questions or help them couple their
existing systems to new technologies, and the ability of
commercially viable technologies generated by high-tech
companies to attract government funding and shape
entirely new academic research directions. It might be
argued that Affymetrix is a special case since, with its star-
cast of consulting scientists, engineers, and successful
entrepreneurs it was so remarkably positioned to take
optimal advantage of the networks supporting innova-
tion. To address such concerns we chose four case studies
that represent different trajectories microarray technology
could take. Affymetrix was a startup. But what about a
large, well established firm with large internal resources to
devote to developing its own technology for entry in the
microarray market? Would it act independently of the net-
work? Or would it draw upon the same regional networks
as Affymetrix in developing its own microarray platform?
What sorts of factors would motivate it to enter the mar-
ket, and what sorts of resources would it draw upon? The
case of Agilent, daughter firm of Silicon Valley giant
Hewlett-Packard provides a striking opportunity to
explore these issues.
More importantly though, these case studies will help to
illustrate in detail how a viable infrastructure of scientific
Number of Microarray Articles by Departmental Affiliation (2000–2005) Figure 6
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research and complementary technologies emerged in the
case of DNA microarrays, motivating universities, indus-
try, and government, each in different ways, to pursue
competitive scientific and commercial opportunities in
the emerging microarray landscape. But gene chips or
DNA microarrays turn out to be only one possible appli-
cation of microarrays. In the case of Symyx we explore
how researchers – indeed researchers intimately con-
nected with the original microarray project at Affymax –
seized the opportunity to launch a new company that
developed the basic idea of the original microarray to vig-
orously pursue combinatorial chemistry in the direction
of non-organic materials science. Quantum Dot provides
an example of a "classic" university startup coming out of
an entirely different technical domain, nanocrystals, and
seizing an opportunity to incorporate its technology as a
component in the DNA microarray system. Our final case,
Perlegen, is a spinoff of Affymetrix itself, focused on lines
of research aimed at extending basic Affymetrix technol-
ogy in ways directly relevant to concerns of the pharma-
ceutical industry. Together these case studies show that
once microarrays got off the ground, players such as these
made the technology an expansive and self-sustaining
force.
Table 9: Selected Organizations Frequently Citing Affymetrix Patents
Citing Organization Description of Relevant Technology Grants
3M Photopatterned DNA chips N
ACLARA BIOSCIENCES Microfluidics for preprocessing of genetic material Y
AGILENT TECHNOLOGIES Ink-jet manufactured DNA chips N
BIOFORCE NANOSCIENCES Mapping nucleotide positions and molecular interactions through atomic force microscopy Y
BIOMICRO SYSTEMS Microfluidic systems to enhance DNA hybridization N
CALIPER TECHNOLOGIES Parallel microfluidic devices for preparation of genetic material Y
CALTECH Protein design, genetic sequence analysis and amplification, size based polynucleotide sorting Y
CEPHEID Rapid genetic testing for diseases and bioterrorism Y
CLONTECH LABORATORIES Glass, nylon, and plastic expression profiling microarrays; disease profiling arrays Y
EASTMAN KODAK Reagents and imaging systems for microarrays N
FUJI PHOTO FILM Electrochemically assembled DNA chips, optical scanners for expression arrays N
GENE LOGIC Analysis of Affymetrix GeneChip data Y
GENOSPECTRA Chronological quantitation of genetic cellular events N
HARVARD COLLEGE Protein arrays Y
HYSEQ Protein modeling and DNA chips Y
ILLUMINA High density optical wells and scanning systems for nucleic acid analysis Y
INCYTE Microarrays for gene expression studies and drug discovery Y
KIMBERLY-CLARK WORLDWIDE Multipurpose optical diffraction biosensors N
LARGE SCALE PROTEOMICS Protein identification and characterization N
LEXICON GENETICS Gene knockout technology to systematically discover the physiological and behavioral functions of 
genes
Y
MIT Nanoparticles to create, through deposition and pattering, microelectronic devices that 
incorporate biological materials. Nanocrystal tagging and tracking of DNA.
Y
MAXYGEN Protein therapy Y
MERGEN DNA chip maker N
MOTOROLA Stamped DNA chips N
NANOGEN Sample preparation and testing tools Y
NANOSPHERE Protein/Nucleic acid detection without amplification Y
NANOSTREAM Microfluidic systems to enhance array throughput N
ORCHID BIOSCIENCES Microfluidic glass chips for identity testing Y
PERLEGEN SCIENCES Whole genome association studies on DNA chips to better match patient genotypes with 
medications
Y
ROSETTA INPHARMATICS Ink-jet microarrays and analysis software for genetic research N
SEQUENOME Resequencing array for genotyping N
SOMALOGIC Rapid protein based diagnosis of disease Y
STANFORD UNIVERSITY Using cell stress response to identify drug targets, nucleic acid amplification, pin based DNA chip 
manufacturing
Y
SYMYX TECHNOLOGIES High throughput chemical discovery and analysis on microarrays Y
TELECHEM INTERNATIONAL Noncontact microspotting devices N
THIRD WAVE TECHNOLOGIES Molecular diagnostics and amplification Y
UNIVERSITY OF CALIFORNIA Flourescense tagging, expression analysis algorithms, diagnostic arrays, chemical discovery arrays Y
UNIVERSITY OF MINNESOTA Creating temperature gradients on DNA chips to better characterize molecular interactions Y
VIALOGY Data cleaning software for gene expression studies N
ZYOMYX Human and murine cytokine protein assays YJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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6.1 Agilent
Agilent officially entered the DNA microarray business
fairly soon after Affymetrix commercially launched its
GeneChip®s in 1998. Agilent got its start in the microarray
business through a collaboration to build scanners for
Affymetrix in the mid 1990s, but the company decided to
compete against its business partner in 1999. Through its
other bio-analysis and lab products and its connections to
HP's printing and scanning business, it already housed
much of the expertise necessary to create its own version
of a DNA microarray and the associated hardware and
software.
To get a sense of how Agilent shifted its research to address
the microarray market, we searched Agilent and HP's pat-
ent portfolios for inventions pertaining to microarray sys-
tems [Note V]. After extracting the inventor names from
220 patents related to microarrays, we created patent
timelines of the 140 or so inventors from these patents
[Note W] to discover whether they had been at Agilent/HP
or another company within the five years prior to their
first microarray patent filing. Out of seventy-three inven-
tors for whom we had the necessary data (we excluded
from the analysis inventors for whom we could find no
previous affiliations), sixty-one (roughly 84%) had been
employees at Agilent or HP before their first patent filing
on a microarray-related technology, while twelve had
moved from other companies within the prior five years.
Most of these employees from other companies came
from biotech firms such as Applied Biosystems, Caliper,
and Abaxis, with the exception of an imaging expert from
Polaroid. We also uncovered two ongoing faculty consul-
tations, one with University of Colorado's Marvin Caru-
thers, a well-known biochemist whose former student
Douglas Dellinger had been hired at the company, and
another with Karin Caldwell, a biochemical surfaces
expert at the University of Utah and Uppsala University in
Sweden. These hires from the biotech sector and the ongo-
ing connections with academia may have served as means
for Agilent to enhance its absorptive capacity [33], as com-
panies such as Affymetrix have benefit significantly
through collaborations with academics who help them
integrate state of the art knowledge from different fields
into their technology.
It also cannot be ignored that Agilent may have taken
much longer in entering the business or may have never
gotten started in microarrays had it not been for Affyme-
trix's lead. While Agilent did not receive government sup-
port for its research in this area, it did engage in many of
the other formal relationships that characterize a net-
worked innovative firm, such as partnering with Affyme-
trix early on for scanners and then collaborating with and
investing in Rosetta Inpharmatics (founded by Stephen
Friend, formerly a faculty member of Harvard Medical
School; Leland Hartwell, Nobel Prize in Medicine in
2001; and Leroy Hood, then chair of the molecular bio-
technology department at the University of Washington).
Led by Alan Blanchard and Leroy Hood, Rosetta had
devised an early ink-jet microarrayer based on Epson
printers prior to its collaboration with Agilent, but part-
nership resulted in the use of Agilent ink-jet arrayers and
Rosetta's bioinformatics software. Yet in filling the tradi-
tional role of a large company that quickly follows a star-
tup into a new market (sometimes referred to as the "fast
second"), Agilent did help to lower the costs of using
microarrays and offered a new set of feature choices to
consumers (such as ease of customizability) that they may
not have had with a single commercial gene chip provider.
Even a company as diversified and seemingly well-posi-
tioned to entering the microarray business as Agilent still
received benefits from participating in this larger network
of activity surrounding high-throughput gene expression
monitoring technologies. In addition to the ongoing aca-
demic consultants it retained, the company sent its
researchers to numerous scientific conferences and collab-
orated on several papers with academics. Through early
2006, Agilent researchers had appeared as authors on over
forty microarray papers, most of which were in collabora-
tion with academic institutions such as Duke, Stanford,
the University of Southern California, Michigan Univer-
sity, Washington University, and NC State [Note X].
Although this is common in companies with large
research divisions, we believe it is an often overlooked,
key source of project ideas and technical guidance. 
While Agilent hired several people to work in its newly
formed microarray business, the convergence of expertise
from scanners, printers, software, microfluidics, and chro-
matography equipment toward complete microarray sys-
tems within its own organization can be seen in the
research trajectories of its scientists. Lead researchers at
Agilent often acted as the central bridge gathering those
with different backgrounds around microarray printers
and scanning systems. These researchers themselves came
from one specific field or another, such as ink-jet printing,
lab instrumentation, or biochemistry, but their changing
research foci can be seen in the patents they filed over
years preceding Agilent's entry into the microarray busi-
ness. For example, HP researcher Michael P. Caren worked
in ink-jet nozzles and cartridges in the early 1990s and
transitioned into creation of arrayers for genetic material
by the late 90s. Many researchers exhibited a similar pat-
tern coming from different areas of HP or outside compa-
nies and eventually coalescing around microarray
technologies such as scanners, printers, and slides.
Agilent settled on a very precise ink-jet based approach to
depositing strands of genetic material at specific sites. ItJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
Page 25 of 39
(page number not for citation purposes)
also developed its own scanners and analysis software.
Eventually, Agilent emerged as the number two micro-
array provider. Agilent's sixty nucleotide arrays offered
very good consistency, while its microarrayers were easy to
customize and provided rapid manufacture of DNA chips.
Agilent's life sciences business includes microarrays,
microfluidics, gas chromatography, liquid chromatogra-
phy, mass spectrometry, informatics tools, and related
reagents [34]. Despite the obvious complementarities
with its existing businesses and seemingly privileged entry
into microarray technologies through its partnership with
Affymetrix, Agilent cannot be seen as a large company
forging ahead on its own. While it did have much of the
expertise necessary to begin this business, Agilent still col-
laborated with universities and actively engaged with the
scientific research community that used microarrays.
The case of Agilent unexpectedly brings forth several
themes we have been exploring in the history of micro-
array technologies. Although the company had a great
deal of the requisite expertise in-house (based on our
analysis of researcher's patent histories) and was well-
positioned to begin its own microarray business (particu-
larly given its connection to Affymetrix through their scan-
ner partnership), Agilent still found it useful to
collaborate with startups, consult with universities, and
engage with the larger scientific community in developing
its technologies. Agilent's strong ties to the research com-
munity and the converging technical concerns of its
researchers underscore the importance of multidiscipli-
nary collaborations and a dialogue with the university-
based and other scientists in developing complete systems
for gene expression studies.
6.2 Symyx technologies
Microarrays not only became a platform upon which var-
ious types of genomics and microbiological technologies
were built; they also provided conceptual inspiration for
the development of an analogous approach to non-bio-
logical materials discovery. The chemicals industry faced
many of the same combinatorial chemistry challenges
that plagued pharmaceuticals: a staggering number of
possible molecular combinations and painstakingly slow
trial and error testing processes. A method of quickly
screening the candidate compounds suggested by combi-
natorial chemistry had been in need for years. Perhaps
unsurprisingly, Peter G. Schultz, a founder of Affymax, the
company that spun out Affymetrix, and at the time a pro-
fessor of chemistry at Berkeley, initially conceived of the
application of high-density microarray techniques to inor-
ganic materials testing.
In the background of his first patent on a high throughput
chemistry chip, Schultz and his co-inventors Xiaodong
Xiang (of UC Berkeley) and Isy Goldwasser (one of his
students who became President of the newly founded
Symyx) explain the need for massive expansion of trial
and error techniques then employed in materials discov-
ery. Similar to the initial problem of screening drug com-
pounds at Affymax, the inventors indicate that given the
low level of scientific understanding of the properties of
materials, the need for massive screening elements against
combinations of other elements requires a massively par-
allel approach [35].
Because chemistry was insufficiently advanced to model
combinations of materials and their resulting properties,
it was necessary to create as many different mixtures as
possible and then conduct numerous laboratory tests to
determine their usefulness. The inadequate screening
methods for such a large range of potential materials rep-
resented a serious bottleneck in materials discovery. The
math governing how combinatorial chemistry had created
a crisis of testing was clear to those in the field, as former
Caltech professor Henry Weinberg, who had been hired
into Symyx, and collaborator James Engstrom of Cornell
write:
"Given n elements [and g elements per material], there are
N = n!/(n-g)!g! possible combinations. Thus, if we restrict
ourselves to 25 [ternary, g = 3] elements we need to syn-
thesize and screen N = 25!22!3! = 2,300 ternaries. If we
form these at 5% precision [and provided G distinct com-
positions], the total number of compositions is approxi-
mately equal to N × G = 2,300 × 231 = 531,300 (the exact
number is 399,025). One sees that even for modest preci-
sion (Δx = 0.05), complexity (g = 3), and diversity (n =
25), the numbers get very large and the experimental
"boost factor" provided by high throughput combinato-
rial approaches is required" [36].
The number of compounds that needed to be screened
against one another was simply too great using traditional
methods, particularly when each process was multiplied
by the need to vary temperature and pressure for each
reaction [37]. Moreover, this new screening system had to
have two major phases, the first in which it simply meas-
ured the reactivity of various polymers and a second, in
which it another battery of tests could assess the "chemi-
cal, optical, mechanical, and electronic properties of large
arrays of materials" [38].
The conceptual similarities of measuring reactions at
known sites between gene chips and the new materials
discovery arrays were described in a Symyx patent relating
to manufacturing techniques:
The oligonucleotide probes, in turn, are available to par-
ticipate in a hybridization reaction with selected nucleicJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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acid components of the sample. Generally, this interac-
tion of probe and sample relates to the utility of the com-
ponents of the biological sample, such as the identity,
concentration, purity or form of the components being
sensed [39].
In comparison, in the case of Symyx arrays, an overhead
infrared camera would detect how much heat had been
emitted from each well, indicating to what extent the
combined chemicals had reacted. However, other Symyx
disclosures were quick to point out that the analogies
ended at the conceptual level. Although the microarray
was the essential platform that motivated the formation
of Symyx, the technical challenges of implementing a
materials array were quite different from those posed by a
DNA chip. In the background of their early patent filings,
regarding their technical approach to massive chemical
screening and its dissimilarities to biological microarrays,
Schultz and colleagues write:
"These solid phase synthesis techniques, which involve
the sequential coupling of building blocks (e.g., amino
acids) to form the compounds of interest, cannot readily
be used to prepare many inorganic and organic com-
pounds" [40].
While the technology for building the chips was different,
the overall process of screening using the microarray plat-
form in the cases of genes and chemicals was quite simi-
lar. In their article explaining the process of materials
screening employed by Symyx, Murphy et al. provide two
workflows (Figure 7) outlining the underlying technolo-
gies for high-throughput screening and the ways Symyx's
new on-chip techniques altered the discovery process for
chemicals companies [41].
Similar to the benefits derived from using massive gene-
expression monitoring technologies, the advantage to
users of the technology primarily came in the form of bet-
ter targets for further research (as opposed to stumbling in
the dark or working with the few targets whose properties
are known). In the figure on the right, Murphy et al. indi-
cate the disciplines underpinning each part of the discov-
ery process using Symyx arrays. This is largely analogous
to the fields involved in each facet of DNA chip technol-
ogy, with biology and biochemistry substituted for phys-
ics and physical chemistry. Indeed, research teams at
Symyx often consist of chemists, physicists, engineers and
programmers.
In addition to addressing analogous scientific and techni-
cal challenges to the GeneChip®, Symyx got its start in
much the same way as Affymetrix. Apart from the two
companies being based around a technology originally
conceived of at Affymax, and sharing founders Schultz
and Zaffaroni, the company maintained collaborations
with academic institutions such as UC Berkeley and Uni-
versity Frechet and early on hired chemical engineering
professor W. Henry Weinberg from Caltech to be execu-
tive vice president and chief technical officer. Kenneth J.
Nussbacher, a fellow and executive vice president at
Affymetrix, sits on the board of Symyx.
The company raised venture capital funding in addition to
receiving a few government grants (Table 10). One gov-
ernment grant was aimed at discovering new materials for
methanol fuel cells.
Workflow for Chemicals Discovery and DisciplinaryUnderpinnings of Symyx High-Throughput Screening Figure 7
Workflow for Chemicals Discovery and DisciplinaryUnderpinnings of Symyx High-Throughput Screening. Fig-
ures reproduced with the kind permission of Symyx Technologies, Inc.Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Yet the greatest source of funding for the company came
from its large industrial partners with whom it has ongo-
ing materials discovery programs. Symyx's customers,
such as Celanese, Ciba, Dow, Osram OS (Siemens), and
Unilever, had contributed over $85 million in near term
research funding by 1999 (Table 11) [42]. Symyx has
already helped to develop and a variety of materials for
different purposes, including oil refining catalysts, chemi-
cals for sensor applications, and polymers for personal
care products.
Thus, Symyx's approach, which it claims is 100 times
faster and 100 times cheaper than traditional research
methods [43], allowed it to take the microarray platform
into a variety of new sectors. In this case, it was research
and licensing partnerships with established firms who
had a need for materials with particular properties. Unlike
Affymetrix or Agilent, which sell chips and the associated
systems to customers, Symyx can be seen as more of a serv-
ice provider to large companies, with its income primarily
stemming from licensing royalties, using the microarray
platform and a team of experts with diverse backgrounds
to discover materials based on clients' needs. Although
outsourcing of gene expression studies occurs regularly, it
would be interesting in future research to understand why
the Symyx approach has remained in house (for example,
is this due to technical and/or market considerations?).
Symyx represented an important foray into new applica-
tions for the microarray platform. Developing and com-
mercializing the technology drew upon the set of actors
we have been discussing. With the key technology being
developed by academics and remaining tightly woven
into cutting-edge chemistry, physics, and engineering,
Symyx developed a method of high throughput screening
that appealed to a broad set of large customers in different
industries. Its academic background and long-term
research partnerships with established firms account for a
great deal of the success of Symyx's discovery tools and
processes.
6.3 Quantum dot corporation
We now turn to the history of a startup that provided
improved components for the microarray platform rather
than seeking to provide technological competition for the
gene chip or to prove a new application for microarrays as
the organizations in the prior case studies have. In fact,
this technology did not even come out of the labs of users
Table 11: Licensed Symyx Discoveries
Licensee Technology
Commercialized Materials
Agfa DirectriX needle-based detector technology for
Dow Catalysts to produce VERSIFY™ Elastomers and Plastomers
DX-S Computed Radiography
JSR Polymers for Electronic Material
Technologies in Development
Canon Lab instruments
Celanese Catalyst for Commodity Chemicals
Dow Various Polyolefin Catalysts
Exxon Mobil Catalyst for Commodity Chemicals
Exxon Mobil Refining Catalyst
Hella Automotive Oil Sensor
INEOS Commodity Chemical Catalyst
Unilever Personal Care Polymer
Univation Polyethylene Monitoring Sensor
Unspecified Catalyst for Electronic Applications
Unspecified Sensor for Oil and Gas Exploration
Unspecified Oral Care Polymer
Table 10: Government Funding to Symyx
Government Entity Start Date End Date Total Funding Avg FY Fund Abstract
DOD – NAVY 9/1/1998 6/1/2001 NA 1146.75 NA
DOD – NAVY 7/1/1997 1/1/1998 NA 34.5 NA
DOE – Basic Energy Sciences 8/1/1997 6/1/2000 825.382 206.346 A combinatorial approach to the synthesis and 
characterization of novel anode materiasantar 
direct methanol fuel cellsJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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of gene expression microarrays who wanted to enhance
their performance; instead, it came from the field of quan-
tum nanocrystals (small groupings of electrons with prop-
erties similar to an atom) that physicists and chemists had
begun exploring seriously in the 1980s. Having spent
years fine-tuning these crystals, but struggling to find a
compelling application for them, several research teams
began pursuing their use as biological labels when they
realized that they were the perfect size for attaching to
organic molecules. Since the GeneChip® was receiving
much attention at the time and many were aware that the
existing fluorescent labels made it difficult to read the
chips at higher densities, applying the new labeling tech-
nology in the rapidly growing DNA microarray industry
was a natural choice.
In a retrospective portion of an article, Paul Alivisatos of
UC Berkeley, one of the major pioneers in using quantum
dots as biological labels, explains that the technology
emerged from a exciting area of research for many physi-
cists because of the ability to control the energy properties
of quantum dots by changing their size. After a period of
refining techniques to maintain quantum dots in solu-
tion, researchers seized upon their potential biological
applications because the entire structure was roughly the
size of a protein [44].
Quantum dots, groupings of free electrons that have prop-
erties very similar to atoms, had been a subject of research
inquiry for chemists and physicists beginning in the
1960s. In the late 1990s, researchers at several schools,
including UC Berkeley, Indiana University, and MIT, real-
ized that quantum dots could be used to replace fluores-
cent dyes used in microarray studies. These dyes often did
not provide sufficient contrast, particularly when genetic
sequences were placed very close to each other as in high-
density chips. Quantum dots offered greater clarity and
because of their consistent and highly specific wavelength
response, they offered potential to tag the genetic
sequence with additional information. In September of
1998, Science published back-to-back articles by the com-
peting research groups from UC Berkeley and Indiana
University on the use of quantum nanocrystals as a track-
ing tool for biological material. As the two foundational
articles explain:
"The development of nanocrystals for biological labeling
opens up new possibilities for many multicolor experi-
ments and diagnostics. Further, it establishes a class of flu-
orescent probe for which no small organic molecule
equivalent exists. The tunability of the optical features
allows for their use as direct probes or as sensitizers for tra-
ditional probes" [45].
In comparison with organic dyes such as rhodamine, this
class of luminescent labels is 20 times as bright, 100 times
as stable against photobleaching, and one-third as wide in
spectral linewidth. These nanometer-sized conjugates are
water-soluble and biocompatible [46].
Quantum dots offered dramatically smaller, clearer, and
more descriptive tags for biological molecules. Because
quantum dots could be tuned to a variety of wavelengths,
they could be used to represent much more information
than the two dyes used in microarray experiments. In fact,
this tunability and signal strength offered the potential for
creating gene expression tests that did not even require
probes to be placed at specific sites. As explained in the
background to a patent filed by the MIT quantum dot
group, a particular nanocrystal could emit a wavelength
corresponding to a specific gene sequence:
The system of the present invention, in contrast to fluores-
cently labeled probes used in the existing methods [DNA
chips], is capable of not only acting as a probe for identi-
fication of a desired sequence, but is also capable of
encoding information about the sequence itself. Because
the inventive identification system is capable of providing
both a probe and identifier, ordered arrays are not neces-
sary for accessing genetic information, although the
inventive system can still be used in traditional arrays.
Instead, a collection of beads, for example, can be assem-
bled with the desired labeled DNA fragments, wherein
said beads are also encoded with information about the
particular sequence. Upon binding, the oligo that hybrid-
izes to the sample DNA can be detected by scanning the
sample to identify the quantum dot labeled probe, while
at the same time the sequence information can then be
decoded by analyzing the quantum dot "barcode" [47].
While the initial opportunity for becoming involved with
the rapidly emerging microarray market was attractive, the
superior signal strength and ability to tune a probe to rep-
resent particular information had actually opened up
countless tracking applications. Paul Alivisatos and his
collaborators were especially eager finally to apply and
commercialize their longtime basic research in the form
of a biological label. When Joel Martin, a serial entrepre-
neur and former chemist interested in the technology vis-
ited the Berkeley Lab in 1997, the two began working out
their ideas for a business, and founded Quantum Dot
Corporation in 1999 [48]. QDC retained the primary
investigators (Paul Alivisatos from Berkeley, Shuming Nie
from Indiana, and Moungi Bawendi from MIT) from the
three competing research groups as scientific advisors
while hiring their former graduate students to work in its
labs [Note Y]. QDC also licensed key patents for its busi-
ness from Berkeley, Indiana, and MIT [49].Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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It is likely the widespread importance of nanocrystal tags
helped Quantum Dot Corporation attract government
and venture capital funding. The company received gov-
ernment grants before and after securing an impressive
amount of venture capital funding. In early 1999, the
company raised $7.5 million and in 2000 it raised an
additional $30 million from several venture capital firms
[50]. However, toxicity issues in the fundamental design
of the tags delayed commercialization of the technology,
seriously compromising its business prospects and its
advantage as the first to commercialize this technology.
The slowdown in the development of this promising tech-
nology prompted the government to step in with a major
grant in 2004 to overhaul QDC's nanocrystals and to
lower the cost of manufacturing the multipurpose labels.
Table 12 shows the government grants received by Quan-
tum Dot, including one to redesign its technology[51].
The Federal government through the National Cancer
Institute funded the development of quantum dots as an
in vivo probe for breast cancer and as a better label for
microarray studies, which would greatly cut down on the
amount of genetic material required to conduct a study.
The government also gave its most generous grant four
years later through the Advanced Technology Program to
develop quantum dot probes without cadmium, a poten-
tially harmful substance in many environments. It also
sought to improve QDC's manufacturing processes in
order to dramatically reduce the cost of nanocrystal
probes.
Quantum Dot Corporation established a variety of ongo-
ing collaborations with universities and other companies
to create new applications for its technology and build
complementary lab equipment (Table 13).
Apart from a more typical partnership as exemplified by
its collaboration with Panasonic to build necessary lab
instrumentation, QDC investigated a variety of imaging
applications enabled by nanocrystal tags through its col-
laborations with Genentech, Cornell, Carnegie Mellon,
and Vanderbilt. The latter three research partnerships
demonstrated that quantum dots could serve as tracking
and labeling systems in many biological settings and rein-
force the notion of university research changing in
response to the introduction of (what had become) an
industry technology.
The story of Quantum Dot Corporation reflects that of
Affymetrix in a few ways. The area of quantum dot nan-
otechnology was quite distant from the life sciences it
eventually served before the advent of the gene chip and
the enhancements to nanocrystals in the 1980s and 1990s
that made them suitable as bright and reliable tags for
DNA sequences and other biomolecules. While DNA
microarrays provided an attractive and growing market to
target, government funders, university collaborators, and
industry interest prodded QDC to apply the nanocrystal
tags in a variety of environments with results far exceeding
those of previous labeling systems. Quantum Dot's begin-
nings in three universities, its ongoing ties to those insti-
tutions, and its efforts to develop its technology through
collaborations with other academics demonstrate the
two-way exchange we have been discussing. While the
emergence of the GeneChip® caused the original univer-
sity physicists and chemists behind Quantum Dot to shift
their research to develop particular labeling applications,
the company later received input from a variety of aca-
demic experts on how to extend its basic technology into
new settings. Figure 8 provides illustrations of quantum
dots, their scaffoldings, and how they help to label differ-
ent parts of a cell [52].
6.4 Perlegen
Perlegen is our final case study in the microarray space
because the company represents a significant extension of
the DNA microarray into the pharmaceutical industry
through the profiling of the entire genome on a set of high
density chips. Perlegen has taken the GeneChip® devel-
oped by Affymetrix and repurposed it specifically to
address the role genetic diversity and variation can play in
improved drug targeting and drug discovery.
Table 12: Government Grants to Quantum Dot Corporation
Funder Yearly Amt. ($K) Start Date End Date Description
NCI 207.9 8/1/2000 2/1/2003 Development of quantum dots as tissue probes for concurrent screening of multiple 
markers of breast cancer
NCI 53.7 8/1/2000 7/1/2001 Enhance the sensitivity of DNA microarrays by three orders of magnitude using 
quantum dots, with the goal of enabling single molecule detection
ATP 1000 12/1/2004 11/30/2007 Quantum dot adoption has been slowed because they contain cadmium, which can be 
toxic to humans and can act as a pollutant in the environment. Quantum Dot 
Corporation will create new nanocrystal tags without cadmium and at the same time 
implement manufacturing processes that are 1000 times faster and cut costs of 
production by 90%.Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Affymetrix spun off Perlegen to focus on whole genome
scanning and providing genomics services to the pharma-
ceutical industry. The new company used Affymetrix's
largest, highest density arrays to discover the differences in
individual's DNA relevant to the treatment of a particular
disease. To discover such differences, patient groups are
assembled along clearly defined lines (such as the efficacy
of a particular drug). Instead of using a test of a few hun-
dred genes suspected to be involved, Perlegen's method
allows for an in-depth genome-wide scan of each patient.
These types of tests were the first to uncover the sets of
SNPs linked to the development of particular diseases,
and of more immediate importance, which genetic pro-
files lent themselves well to particular treatments.
Perlegen fills an important gap in the genomics space. It
builds a significant bridge to the pharmaceutical industry
that had previously targeted drugs at patients based on
clinical diagnoses, which were often a group of symptoms
or other phenotypic markers that conflated many possible
genetic underpinnings of a disease. The company helps
pharmaceutical firms identify sub-populations that will
respond safely and more effectively to particular drugs.
The ability to target drugs at specific populations based on
their genetic differences allows for faster FDA approval,
the resurrection of failed drugs, and the application of
existing drugs to new conditions (which can be a means
for filing a new patent on the compound and extending
the time the drug is on patent protection). Perlegen also
hopes to leverage the data it generates to conduct internal
drug development.
From its beginnings, the company was closely connected
to the scientific community. Affymetrix founder and CEO
Quantum Dots Figure 8
Quantum Dots. Images reproduced with the kind permission of Invitrogen Corporation (owner of Quantum Dot Corpora-
tion).
Table 13: QDC's Corporate and University Partnerships
Collaborator Relationship
Panasonic Development and manufacture of instrumentation for Qdot detection
Genentech Drug development, including imaging blood vessel tissue containing the Her-2 cancer-related gene, which is the target of 
Genentech's drug Herceptin
Cornell Highly detailed imaging of blood flow using multi-photon microscopy and nanocrystals
Carnegie Mellon Deep tissue imaging in living organisms
Vanderbilt Nanocrystal tracking of neurotransmittersJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Steve Fodor asked David Cox, then professor of genetics
and pediatrics at the Stanford School of Medicine to be
chief scientific officer at the new company. Early on, Per-
legen published scientific studies based on the results of
its mapping of SNP markers in different populations. Cox
hired his former graduate students to lead the labs and set
up an environment that was characteristic of an academic
research group. The company's researchers had published
close to thirty scientific articles in peer-reviewed journals
as of March, 2006. Within these articles, collaborations
with academics from universities, other non-profit institu-
tions, and companies were frequent (see Table 14).
It was important for Perlegen to attract top scientists and
maintain a porous research environment in which lab
members were free to collaborate with academic col-
leagues as needed. The multiple papers the company
authored with UC Berkeley, Rockefeller, and UC San Fran-
cisco were evidence of this, and the topics ranged from
cross-species genomic comparisons to a haplotype map of
the human genome based on research by hundreds of
International Haplotype Consortium members.
Perlegen was also similar to an academic research group
and the other small companies we have been discussing in
receiving a substantial amount of government funding
(Table 15).
The federal government also funded specific research
projects at the company apart from supporting its broader
goals of mapping important variations in the human
genome. For example, the National Institutes of Mental
Health funded a project to look at genes causing Autism,
and the National Institute on Aging sponsored research to
identify Alzheimer's associated genes.
In addition to the significant interest in Perlegen's tech-
nology and process by the government and academics,
Perlegen's commercial potential attracted the interest of
venture capital firms and pharmaceuticals seeking to
establish partnerships. In fact, Perlegen raised $207 mil-
lion from VC firms since its inception, an impressive
amount in any sector. Pfizer also invested $50 million in
the company, representing 12% ownership.
Indicating the relevance of Perlegen's approach to phar-
maceutical discovery and drug targeting, its clients include
Pfizer, GlaxoSmithKline, Merck, Johnson & Johnson, and
AstraZeneca.
Despite its unique role in serving the pharmaceutical
industry, the networked character of Perlegen, through
venture capital funding, its origins in Affymetrix, the
transplanting of academic researchers into its labs, and its
ongoing collaborations with the scientific community
demonstrates the potential for many of these different
institutions to engage one another simultaneously.
Conclusion
In this study we have explored the dynamics of innova-
tion in a networked technology region, Silicon Valley. Our
study confirms the picture put forward by a several
researchers that the open character of this economy is
what makes it truly innovative. In an open system innova-
tions emerge from the network. The emergence and diffu-
sion of microarray technologies we have traced here
provides an excellent example of an open system of inno-
vation in action. Whether they originated in 1a startup
company environment that operated like a think-tank,
such as Affymax, the research labs of a large firm, such as
Agilent, or within a research university, the inventors we
have followed drew heavily on knowledge resources from
all parts of the network in bringing microarray platforms
to light.
Another key point in our study is the role of federal fund-
ing in stimulating the innovation networks associated
with the emergence and diffusion of microarray technol-
ogy. Federal funding for high-tech startups and new
industrial development was important at several phases in
the early history of microarrays. As we have seen, federal
funds were the enabling factor for several startups, and as
the technology evolved, support for collaborative research
projects using gene chips and microarrays was crucial to
evolving the various microarray platforms and their sup-
porting technologies. Companies developing microarray
technologies such as Affymetrix and Perlegen have func-
tioned very much like research programs at universities,
and in many ways the collaborative research going on in
those firms with academics is more productive and has a
greater impact than research in most university settings.
Table 14: Perlegen Coauthorships with Selected Organizations
Collaborator Authorships Articles
UC Berkeley 4 3
Rockefeller Univ 4 3
UC San Francisco 3 2
Hyseq Pharmaceuticals 3 1
Mayo Clinic 3 1
Kyushu Univ, Japan 2 1
UC San Diego 1 1
Univ Chicago 1 1
Univ Michigan 1 1
Univ Penn 1 1
Brown Univ 1 1
University of Southern California 1 1
Pfizer 1 1
Eli Lilly & Co 1 1
Aventa Biosciences 1 1
Sugen Inc 1 1Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Federal funding of academic researchers using microar-
rays was fundamental to transforming the research agen-
das of several fields within academe. The typical story told
about the role of federal funding emphasizes the spillo-
vers from federally funded academic research to industry.
Our study has shown that the knowledge spillovers
worked both ways, with federal funding of non-university
research providing the impetus for reshaping the research
agendas of several academic fields.
In the early days of the Human Genome Project (HGP)
Walter Gilbert pointed to a paradigm shift about to trans-
form biology as a result of the efforts to sequence the
genomes of all organisms and store that information in
large electronic databases [53]. At the heart of this revolu-
tion were automated computer-based systems for the
massive throughput of biological information and tech-
nology that would allow biologists to perform thousands
of experiments in parallel. Gene sequencing technology,
including PCR machines, laboratory robotic systems, such
as the arrayers we have discussed, bioinformatics software
such as, FASTA, BLAST, PSI-BLAST, hidden Markoff mod-
els, and other sensitive tools for imaging and interpreting
sequence information: these and other tools for auto-
mated acquisition and mapping of genetic sequence infor-
mation were products of the Human Genome Project, all
enabling elements of the revolution in molecular biology
anticipated by Gilbert. Microarrays are among the signa-
ture technologies of this ongoing Genomics Revolution.
There are important parallels between the revolution in
molecular biology ushered in by the Human Genome
Project and the revolution in computing and information
technology presided over by the NSF and DARPA's Infor-
mation Processing Technology Office in the 1960s–1970s
[54,55]. Both were large scale federally funded efforts that
provided support to academic research and industry start-
ups – literally creating the field of computer science and a
nascent computer industry on the one hand and the vari-
ous academic, medical and commercial fields related to
genomics on the other. In our view, the infrastructure of
federal funding policy was crucial for enabling the
Genomics Revolution. Over the span of 15 years – from
1988 through its completion in 2003 – the Human
Genome Project expended more than $3.8 billion dollars
in federal grants and contracts to universities, genome
research centers, and industry. From the start, HGP plan-
ners anticipated and promoted private sector participa-
tion in developing and commercializing genomic
resources and applications. When the HGP was initiated,
vital automation tools and high-throughput sequencing
technologies had to be developed or improved. The HGP
leadership recognized these goals could not be achieved
within the timeframe set for the Project without comple-
mentary efforts of both university and private sector
researchers. The strategy succeeded beyond anyone's
expectations: the cost of sequencing a single DNA base
was about $10 at the outset of the HGP; by 2001, sequenc-
ing costs had fallen about 100-fold to $.10 to $.20 per
base. DOE-funded enhancements to sequencing proto-
cols, chemical reagents, and enzymes contributed sub-
stantially to increasing efficiencies and reducing costs. The
commercial marketing of these technologies greatly bene-
fited basic R&D, genome-scale sequencing, and lower-cost
commercial diagnostic services. As we have shown in the
case of microarrays, substantial public sector R&D invest-
ment by the DOE and the NIH launched key startup ven-
tures such as Affymetrix, Synteni, Incyte and other firms;
and as we have also shown, federal funding of research
collaborations between academic and industry research-
ers at these companies improved the technology and
reshaped the academic landscape. In addition to the HGP
Table 15: Federal Funding to Perlegen
Funder Start Date End Date Avg FY Fund ($K) Title
National Cancer Institute 9/1/2004 8/1/2005 209.8 Comprehensive Mutational Analysis of the Cancer Genome
National Human Genome 
Research Institute
9/1/2004 9/1/2005 3041.8 Large-Scale Low-Cost Genotyping for the Haplotype Map
National Human Genome 
Research Institute
9/1/2002 6/1/2005 260.7 Evolutionary Conserved Sequences in the Human Genome
National Human Genome 
Research Institute
6/1/2003 3/1/2004 50.3 Comparative Microarray Sequencing of Chimpanzee genomes
National Institute of Allergy 
and Infectious Disease
8/1/2003 7/1/2004 250 Discovery of Salmonella signature SNPs by microarrays
National Institute of Arthritis 
and Musculoskeletal and Skin 
Diseases
9/1/2004 3/1/2005 110.9 Genetic Association of Rheumatoid Arthritis
National Institute of General 
Medical Sciences
5/1/1998 4/1/2003 118.6 Conserved regulatory sequences in humans and mice
National Institute of Mental 
Health
8/1/2004 7/1/2005 125 Genetic Association in Austism Disorder
National Institute on Aging 8/1/2004 1/1/2005 283 Genome-Wide Scan for Alzheimer's Associated GenesJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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itself, the key policy instrument enabling these develop-
ments was the Small Business Innovation Development
Act of 1982, which created the Small Business Innovation
Research (SBIR) and Small Business Technology Transfer
(STTR) programs [56] [Note Z]. Although not created with
the Human Genome Project in mind, the Small Business
Development Act and the direct federal funding of indus-
try R&D by the NSF, NIH, and DOE provided the basis for
the two-way flow of innovation between academic
researchers and industry that has fueled the Genomics
Revolution.
Notes
[A] Schultz was already celebrated for his contributions to
the understanding of the mechanisms of molecular recog-
nition and catalysis in biological systems. He was working
on the design of highly efficient "catalytic antibodies"
able to cut, splice, and modify biological molecules at spe-
cific points. Schultz was also beginning his pioneering
work on a new technique for studying proteins in which
unnatural amino acids are inserted site-specifically into
proteins so that their catalytic and binding properties and
stability could be studied.
[B] The board included Paul Berg, Carl Djerassi, Mark
Davis, Avram Goldstein and Michael Pirrung from the
Stanford biochemistry, chemistry, and pharmacology
departments; Murray Goodman, from biochemistry at UC
San Diego; and Joshua Lederberg from Stanford and the
Rockefeller University. They met weekly with Zaffaroni,
Schultz, Read, and Lubert Stryer, who was the director of
the board. Stryer had taken a leave of absence from Stan-
ford to head the research team at Affymax.
[C] For an excellent discussion of Geysen's peptides on
pins method and its limitations see Pirrung MC: Molecular
Diversity and Combinatorial Chemistry: Principles and Appli-
cations. Amsterdam: Elsevier; 2004, pp. 17–20. Geysen's
approach involved a strategy of iterative steps, called iter-
ative deconvolution, in identifying the optimum set of
peptide pairings that would identify a protein-binding
region; the Affymax scientific board felt it involved
assumptions that would allow potentially valuable drug
leads to be missed.
[D] Another strategy was Richard Houghten's "tea bag"
approach and the "split-and-mix" synthesis pioneered by
Árpád Furka from Hungary (later at Advanced ChemTech
in Louisville, KY).[1] Kit Lam from the University of Ari-
zona (now at UC Davis) took the split-and-mix method to
the next level in 1991 by growing the peptides as attach-
ments to polystyrene beads as the supports for the synthe-
sis. Lam's highly efficient split-and-mix synthesis method
generated "one-bead one-compound" (OBOC) combina-
torial peptide libraries with millions of peptides, in which
each 80-μm bead displayed only one peptide entity.
[E] The ability to attach and remove molecules using light
to activate or deactivate linkages at different stages of the
synthesis was crucial to Pirrung and Read's ideas for in situ
synthesis. The parallel synthesis in situ on the solid sur-
face using photolithographic techniques depends on
decoupling protective groups followed by coupling of oli-
gonucleotide. In order for synthesis to progress, a protect-
ing group on the 5'-hydroxyl terminus of the growing
DNA molecule must be removed. As demonstrated by the
work of Patchornik and others, this deprotection reaction
is readily adapted to light control through a large class of
protecting groups that are photochemically removable.
With his background in photochemistry, Pirrung was
deeply familiar with the research on photolabile protect-
ing groups in mononucleotide syntheses by Patchornik
and his students dating back to the early 1970s, in addi-
tion to the contributions to the field of a number of other
researchers in the intervening years. For a list of more than
thirty scientific publications relevant to the gene chip see
Fodor SPA, Stryer L, Winkler JL, Holmes CP, Solas DW:
USPTO 5,489,678. Photolabile nucleoside and peptide
protecting groups, February 6, 1996.
[F] Pease's wife, Anna Caviani Pease was first author on
the May 1994 paper in the Proceedings of the National
Academy of Sciences which introduced sequencing by
hybridization on the Affymetrix gene chip. Anna Pease
had her Ph.D. in Chemistry from UC Berkeley in 1990
and joined Affymax shortly after. She also took a law
degree from the Stanford Law School in 1995 and joined
the firm of Dorsey & Whitney in the Stanford Research
Park as Co-Head of the firm's Life Sciences and Health-
care, focusing on strategic aspects of patent law in the bio-
technology, pharmaceutical and chemical fields. Pease
continued to work at Affymetrix, where she became the
chief inventor on several Affymetrix patents on DNA
arrays.
[G] This includes multiple appearances by the same
researcher. To identify these scientists, we extracted all of
the inventors from Affymetrix patents, along with their
state. We matched inventors and states to all US patents to
find all their previous patents and hand classified those
patents to ensure that the inventor was the same individ-
ual. While there was some overmatching and some under-
matching because of common names and individuals
moving across states, we believe this was a fairly complete
process. We then hand-classified unique inventors based
on the subject matter of the patent, which assignees they
were associated with, and temporal/geographic informa-
tion (e.g. you cannot file patents from two different places
at the same time). In addition to identifying previous andJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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contemporary university affiliations, we included of pat-
ents that were co-assigned to a university.
[H] Pirrung moved from Stanford to Affymetrix and then
quickly moved to Duke.
By 2000, when he filed a patent with Affymetrix, Francis
Collins was Director of the National Human Genome
Research Initiative.
The University of California faculty who worked with
Affymetrix were from the Berkeley campus.
Andrei Mirzabekov was also a professor in Russia at the
Moscow Physics-Technical Institute at the time, but we
chose to include his affiliation with Argonne here because
that was how he became involved with Affymetrix.
The reason we say "some" of the faculty who appeared on
the patents is due to our matching process. Because there
were hundreds of Affymetrix inventors we decided to link
them to a larger database of all patents from 1974–2003
using their name and state. We screened these resulting
patents against a table of all assignees to identify potential
university professors (assuming they had filed a patent at
their respective institution). Following our initial match-
ing process, we searched the web for each suspected fac-
ulty person to verify his or her affiliation. Graduate
students or post docs who appeared on the patents were
not included despite the fact that a few of them are now
professors at other institutions.
[I] SBIR and STTR awards are for small companies with
fewer than 500 employees. The PI on the award does not
necessarily have to be a member of the company. For
more information, see: http://www.sba.gov/
[J] NHGRI Grant Number: 5R01HG000813-03
Project Title: Sequence Determination by Hybridization
Principal Investigator: Stephen A. Fodor
Abstract: The long term goals of this proposal are to con-
struct spatially defined arrays of oligonucleotide probes
and to study the feasibility of using these arrays in appli-
cations of sequencing DNA by hybridization. A multidis-
ciplinary research program is proposed which will
integrate the necessary expertise in photolithography,
photochemistry, synthetic chemistry, detection technol-
ogy, informatics and applications to large scale DNA
sequencing. We will apply newly developed techniques in
light-directed polymer synthesis to oligonucleotide chem-
istry, explore kinetic and solvent related parameters of tar-
get hybridization to oligonucleotide arrays, read the
positions of hybridization by epifluorescence microscopy,
and apply new combinatorial methods to determine
sequence from the hybridization data. The method will be
applied to actual sequencing applications at the yeast
genome center. Successful completion of this work will
lead to sequencing instrumentation that will provide
order of magnitude improvements in DNA sequencing




Santa Clara, Ca 95051-0704
Project Start: 25-SEP-1992
Project End: 31-OCT-1995
[K] Radius: https://radius.rand.org. The asterisk* for the
last item in the total column refers to the fact that Radius
has not updated the data for funding received in 2004 and
2005.
[L] Edwin Southern and Uwe Maskos developed an array
on impervious supports comprised of short oligonucle-
otides of up to 19-mer length by in situ synthesis in 1991.
The method used a process of physical masking in con-
trast to the light directed synthetic method developed by
Fodor, et al. at Affymetrix. Southern filed for a US patent
on this process in 1994. See Southern EM: USPTO
5,700,637. Apparatus and method for analyzing polynu-
cleotide sequences and method of generating oligonucle-
otide arrays, December 23 1997.
[M] Based on our analysis of the first 130 articles pub-
lished regarding DNA chips. We used author affiliations
to count institutions, thus one article could add more
than one institution to these totals. The exact search query
in Google Scholar (which allows for full text article search-
ing) and Web of Science (in the TS field, with a slightly
different query format): microarray OR "gene chip" OR
genechip OR "DNA array" OR "oligonucleotide array" OR
"DNA chip" OR "cDNA array" OR "cDNA chip" OR "oli-
gonucleotide chip". We then found all the pre-1999 arti-
cles in Web of Science (which contains better
bibliographic information for download). We were not
overly concerned with finding every early microarray
paper, we simply needed a sample of those papers. More-
over, it is likely that early users of microarrays were more
likely to make the use of the technology a more promi-
nent feature of the paper than later users both to highlight
its novelty and to justify their approach, once the practice
had become more customary. Thus, we expect that a largeJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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proportion of these early studies using microarrays explic-
itly referred to their methods and equipment. Approxi-
mately 60% of our search results were false positives
(mostly due to "microarray") and these were eliminated
from the dataset by reading the methods section of the
paper (or some part of the discussion if it was a forecasting
article), this left us with 130 papers. The entire search was
independently checked for completeness on PubMed
using the MeSH controlled terms (which added only one
or two articles to our dataset) and by using Affymetrix's
list of publications using DNA microarrays.
[N] We used VxInsight from Sandia Labs and its module
VxOrd to do the initial placement of organizations
according to their coauthorship patterns. We used the
resulting coordinates in KiNG (available free from the
Duke Biochemistry Department website: http://kine
mage.biochem.duke.edu/software/king.php) to do the
final visualization.
[O] There were also several organizations that had collab-
orated separately but did not connect to this larger net-
work of early research. These largely included research
efforts in Korea, Taiwan, Finland, and Germany, but also
included a few articles published by U.S. based authors
that did not link up with the rest of the early research.
[P] Note that this distribution is heavily skewed toward
2000–2004, and continued to rise through 2004
(although we did not have complete coverage of 2004). A
major uptick occurred beginning in 1999/2000, when
gene chips officially hit the market. The grants in the early
years were very long term grants that had microarray
projects added in during later years.
[Q] Based on our searches within Radius. We believe that
proposed studies making use of DNA chips have become
less likely to mention the technology as it becomes more
commonplace, which would mean that we capture a
smaller fraction of newer studies making use of the tech-
nology as compared with older government proposals,
despite the overall rising trend.
The query we used, after experimenting with the useful-
ness of various search terms, was: "gene chip" OR gene-
chip OR "gene array" OR "gene microarray" OR "dna
microarray" OR "dna array" OR "dna chip" OR "cdna
microarray" OR "cdna array" OR "cdna chip" OR "oligo-
nucleotide array" OR "oligonucleotide chip" OR "oligo-
nucleotide microarray"
Washington University is based in St. Louis and is separate
from the University of Washington system.
[R] Cite* (total citations from each category) reflects the
number of articles in each category that cited the first 130
microarray-based studies. The articles were weighted by
the number of times they cited the first 130, because we
believed that this is an indication that the article is more
relevant to microarrays. In addition, in most cases articles
had multiple category classifications. We decided not to
divide each article by the number of classifications it had
because those articles with multiple classifications were
more likely to be those of interest to us and, it can be
argued that we should not risk downplaying the impor-
tance of an article due to the arbitrariness of a classifica-
tion system. We decided to exclude categories that were
not useful, such as Multidisciplinary Sciences and Multi-
disciplinary Chemistry.
[S] According to our keyword searches within the Scopus
database. The keywords we used were similar to those
above: "gene chip" OR genechip OR "gene array" OR
"gene microarray" OR "dna microarray" OR "dna array"
OR "dna chip" OR "cdna microarray" OR "cdna array" OR
"cdna chip" OR "oligonucleotide array" OR "oligonucle-
otide chip" OR "oligonucleotide microarray"
[T] We considered organizations that cited Affymetrix pat-
ents fourteen or more times and used normalized assignee
names to avoid undercounting because of typographical
errors and acquisitions.
[U] In this case, we present the organizations that cited
Affymetrix fourteen or more times, fourteen was only cho-
sen in the interest of space. The reason we describe these
organizations as "selected" is that we excluded a few
organizations because the technology they developed was
not very innovative or if there were already enough exam-
ples of assignees on the list that were very similar. We also
excluded companies with technology that was tenuously
related to DNA microarray technology. Incyte changed its
name and the total number of citing patents was fifteen.
[V] We used a three step query based on keywords, classi-
fications, and inventor names for this search. We tested
this method on Affymetrix's patent and application port-
folio and found 630 out of 633 of its patents. While this
query method could be improved, it was not necessary for
our purposes to find every single Agilent/HP patent on
microarray-related systems, nor was it crucial that we
exclude every single invention that was not related to
microarrays.
[W] We did this by matching inventor names and state/
country locations to prior patents. We made common
sense assumptions such as inventors not being able to file
from multiple locations on different types of technologies
at the same time. We also assumed that inventors whoJournal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Appendix A: Total Citations to Early Microarray-Based Studies by Field
Field of Study Cite* Field of Study Cite*
Biochemistry & Molecular Biology 4474 Medical Informatics 82
Biotechnology & Applied Microbiology 2889 Agronomy 71
Genetics & Heredity 2509 Ophthalmology 70
Biochemical Research Methods 1997 Dentistry, Oral Surgery & Medicine 70
Oncology 1822 Radiology, Nuclear Medicine & Medical Imaging 69
Cell Biology 1507 Computer Science, Information Systems 69
Chemistry, Analytical 920 Veterinary Sciences 69
Pathology 759 Agriculture, Dairy & Animal Science 57
Microbiology 756 Nutrition & Dietetics 51
Pharmacology & Pharmacy 664 Transplantation 48
Computer Science 663 Horticulture 48
Statistics & Probability 658 Electrochemistry 48
Immunology 621 Otorhinolaryngology 47
Biophysics 616 Evolutionary Biology 45
Mathematics 612 Parasitology 45
Plant Sciences 605 Optics 43
Medicine, Research & Experimental 553 Computer Science, Theory & Methods 42
Neurosciences 431 Geriatrics & Gerontology 39
Hematology 370 Anatomy & Morphology 38
Medical Laboratory Technology 354 Automation & Control Systems 37
Biology 301 Substance Abuse 36
Virology 278 Polymer Science 36
Public, Environmental & Occupational Health 270 Physics, Condensed Matter 36
Toxicology 259 Pediatrics 36
Endocrinology & Metabolism 254 Information Science & Library Science 34
Physiology 246 Marine & Freshwater Biology 31
Chemistry, Physical 217 Critical Care Medicine 30
Surgery 213 Zoology 30
Infectious Diseases 206 Ecology 28
Urology & Nephrology 203 Orthopedics 28
Medicine, General & Internal 202 Physics 26
Chemistry, Organic 184 Spectroscopy 25
Psychiatry 180 Allergy 22
Chemistry, Medicinal 167 Microscopy 18
Developmental Biology 165 Materials Science, Biomaterials 17
Gastroenterology & Hepatology 160 Behavioral Sciences 16
Environmental Sciences 133 Computer Science, Hardware & Architecture 16
Materials Science, Multidisciplinary 130 Medicine, Legal 16
Engineering, Biomedical 127 Mechanics 16
Obstetrics & Gynecology 123 Agriculture, Multidisciplinary 14
Food Science & Technology 120 Engineering, Environmental 14
Clinical Neurology 118 Health Care Sciences & Services 14
Reproductive Biology 117 Integrative & Complementary Medicine 14
Respiratory System 116 Computer Science, Cybernetics 13
Computer Science, Artificial Intelligence 115 Materials Science, Coatings & Films 13
Engineering, Electrical & Electronic 113 Sport Sciences 13
Instruments & Instrumentation 108 Physics, Mathematical 13
Peripheral Vascular Disease 107 Physics, Fluids & Plasmas 13
Mycology 89 Rehabilitation 12
Cardiac & Cardiovascular Systems 89 Crystallography 12
Physics, Applied 88 Nuclear Science & Technology 12
Rheumatology 88 Mathematics, Applied 11
Chemistry, Applied 87 Agriculture, Soil Science 10
Dermatology 86 Gerontology 10Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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Appendix B: Organizations Citing Affymetrix Patents
Assignee Cite Assignee Cite
AFFYMETRIX, INC. 3248 SOMALOGIC, INC. 20
AGILENT TECHNOLOGIES, INC. 402 BIOFORCE NANOSCIENCES, INC. 20
LEXICON GENETICS INCORPORATED 292 MASSACHUSETTS INSTITUTE OF TECHNOLOGY 20
~Individually Owned Patent 133 SCYNEXIS CHEMISTRY & AUTOMATION, INC. 20
ZYOMYX, INCORPORATED 126 ISIS PHARMACEUTICALS, INC. 19
LARGE SCALE PROTEOMICS CORP. 123 YALE UNIVERSITY 19
SYMYX TECHNOLOGIES, INC. 106 PACKARD BIOSCIENCE CORPORATION 19
ROSETTA INPHARMATICS, INC. 91 HYSEQ, INC. 18
IRORI 90 LJL BIOSYSTEMS INC. 17
UNIVERSITY OF MINNESOTA, THE REGENTS OF 89 GENOSPECTRA, INC. 17
MOTOROLA, INC. 87 APPLERA CORPORATION 17
CALIFORNIA INSTITUTE OF TECHNOLOGY 77 3 M INNOVATIVE PROPERTIES COMPANY 16
VIALOGY CORPORATION 77 GENE LOGIC, INC. 16
UNIVERSITY OF CALIFORNIA, THE REGENTS OF 73 LINDEN TECHNOLOGIES, INC. 16
SEQUENOM, INC. 72 ARCTURUS ENGINEERING, INC. 16
MAXYGEN, INC. 67 THIRD WAVE TECHNOLOGIES, INC. 16
AFFYMAX TECHNOLOGIES N.V. 60 CORNING INCORPORATED 15
CLONTECH LABORATORIES, INC. 47 DUKE UNIVERSITY INC. 14
DISCOVERY PARTNERS INTERNATIONAL, INC. 46 SIGNATURE BIOSCIENCE, INC. 14
UNIVERSITY OF HOUSTON 45 CANON KABUSHIKI KAISHA 14
CEPHEID 44 PROTOGENE LABORATORIES, INC. 14
AMERSHAM BIOSCIENCES AB 43 CHRYSALIS TECHNOLOGIES, INCORPORATED 14
METRIGEN, INC. 39 PERLEGEN SCIENCES, INC. 14
HARVARD COLLEGE, PRESIDENT AND FELLOWS 39 UNITED STATES OF AMERICA, NAVY 14
ILLUMINA, INC. 38 LARGE SCALE BIOLOGY CORPORATION 13
NANOGEN, INC. 38 EOS BIOTECHNOLOGY, INC. 13
NOVARTIS AG (FORMERLY SANDOZ LTD.) 37 UNIVERSITY OF NORTH CAROLINA 13
CALIPER TECHNOLOGIES CORP. 37 WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 13
ORCHID BIOSCIENCES, INC. 36 CELLOMICS, INC. 13
OLIGOS ETC. INC. 36 PROLUME, LTD. 13
BURSTEIN TECHNOLOGIES, INC. 34 CURAGEN CORPORATION 12
BIOMICRO SYSTEMS, INC. 34 HIGH THROUGHPUT GENOMICS, INC. 12
DAVID SARNOFF RESEARCH CENTER, INC. 30 NUGEN TECHNOLOGIES, INC. 12
BATTELLE MEMORIAL INSTITUTE 30 ABLE SIGNAL COMPANY LLC 12
FUJI PHOTO FILM CO., LTD 29 BECKMAN COULTER, INC. 12
EASTMAN KODAK COMPANY 28 GLAXO WELLCOME INC. 12
KIMBERLY-CLARK WORLDWIDE, INC. 26 HANDYLAB, INC. 11
AVIVA BIOSCIENCES CORPORATION 26 ACLARA BIOSCIENCES, INC. 11
UNIVERSITY OF TEXAS 26 BOSTON UNIVERSITY 11
PICOLITER INC. 26 HEWLETT-PACKARD COMPANY 11
APPLIED GENE TECHNOLOGIES, INC. 24 IBM CORPORATION 11
WISCONSIN ALUMNI RESEARCH FOUNDATION 24 HOWARD HUGHES MEDICAL INSTITUTE 11
SARNOFF CORPORATION 23 PHYLOS, INC. 11
STANFORD UNIVERSITY 23 INGENEUS CORPORATION 10
NANOSPHERE, INC. 23 PRINCETON UNIVERSITY 10
NANOSTREAM, INC. 23 QIAGEN GENOMICS, INC. 10
NYXIS NEURO THERAPIES, INC. 22 PROMEGA CORPORATION 10
VERIFICATION TECHNOLOGIES, INC. 21 UNIVERSITY OF MICHIGAN 10
THOMAS JEFFERSON UNIVERSITY 20 STMICROELECTRONICS S.R.L. 10
CORNELL RESEARCH FOUNDATION INC. 20 TELECHEM INTERNATIONAL INC. 10
MERGEN, LTD. 20 EPOCH BIOSCIENCES, INC. 10
Cite reflects the number of times all of the organizations patents cited Affymetrix patents.Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
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appeared to have switched companies and then quickly
moved back, or moved back and forth repeatedly, were
actually different individuals (although we kept an eye
out for university consultants who might have exhibited
this pattern).
[X] Based on a search of the Scopus database: http://
www.scopus.com. The query used was (TITLE-ABS-
KEY(microarray OR "gene chip" OR genechip OR "DNA
array" OR "oligonucleotide array" OR "DNA chip" OR
"cDNA array" OR "cDNA chip" OR "oligonucleotide
chip") AND AFFIL(agilent))
[Y] Interestingly, Moungi Bawendi and Paul Alivisatos,
the heads of their respective labs at MIT and Berkeley had
both worked at Bell Labs in the 80s when major discover-
ies on the properties of quantum dots were made there.
[Z] The Small Business Innovation Development Act of
1982 legislated that 2.5 percent of the budget of any fed-
eral research program with a budget over $100 million
would be devoted to assist small business concerns to
obtain government contracts for their own research and
development, and (in the case of the STTR Program) to
assist collaboration between small business concerns and
federally funded projects at universities or federally sup-
ported research centers for the purpose of transferring the
technology to the commercial sector.
Acknowledgements
The authors are grateful to three anonymous reviewers for extremely help-
ful comments. We are also grateful to our colleagues Wesley Cohen and 
Robert Cook-Deegan for comments and discussion of several drafts of the 
paper. The authors gratefully acknowledge the support of the National 
Human Genome Research Institute and the Department of Energy (CEER 
Grant P50 HG003391, Duke University, Centers of Excellence for ELSI 
Research).
References
1. Kline SJ, Rosenberg N: An Overview of Innovation.  In The Positive
Sum Strategy: Harnessing Technology for Economic Growth Edited by:
Landau R, Rosenberg N. Washington, D.C.: The National Academy
Press; 1986:275-306. 
2. von Hippel E: The Sources of Innovation Oxford: Oxford University
Press; 1988. 
3. Jaffe AB: Real Effects of Academic Research.  The American Eco-
nomic Review 1989, 79(5):957-970.
4. Jaffe AB, Trajtenberg M: Flows of Knowledge from Universities
and Federal Laboratories: Modeling the Flow of Patent Cita-
tions over Time and Across Institutional and Geographic
Boundaries.  Proceedings of the National Academy of Sciences USA
1996, 93:12671-12677.
5. Trajtenberg M, Henderson R, Jaffe AB: Universities as a Source of
Commercial Technology: A Detailed Analysis of University
Patenting, 1965–1988.  Review of Economics and Statistics 1998,
80(1):119-127.
6. Pirrung MC: "The Invention of the DNA Chip (and Peptide
Chip), personal communication.  . May 1, 2000
7. Geysen HM, Meloen RH, Barteling SJ: Use of Peptide Synthesis to
Probe Viral Antigens for Epitopes to a Resolution of a Single
Amino Acid.  Proc Natl Acad Sci USA 1984, 81:3998-4002.
8. Geysen HM, et al.: Strategies for Epitope Analysis Using Pep-
tide Synthesis.  J Immunol Meth 1987, 102:259-274.
9. Fodor SPA, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D: Light-
Directed, Spatially Addressable Parallel Chemical Synthesis.
Science 1991, 251:767-773.
10. Ibid :772.
11. Alexander B: Biopoly Money.  Wired 2000, 8: [http://
www.wired.com/wired/archive/8.06/affymetrix.html]. 06 (June)
12. Gibbs WW: New Chips Off the Old Block – Can DNA micro-
arrays do for genetics what microprocessors did for comput-
ing?  Scientific American 1996:42-44.
13. Stern D, Fiekowsky P: USPTO 5,631,734.  Method and apparatus for
detection of fluorescently labeled materials . May 20, 1997 (Filed 10 Feb-
ruary 1994)
14. Trulson M, Stern D, Fiekowsky P, Rava R, Walton I, Fodor SPA:
USPTO 5,578,832.  Method and apparatus for imaging a sample on a
device . November 26, 1996
15. Winkler JL, Fodor SPA, Buchko CJ, Ross DA, Aldwin L: USPTO
5,384,261.  Very large scale immobilized polymer synthesis using mechan-
ically directed flow paths . January 24, 1995 (Filed 22 November 1991)
16. Hubbell EA, Morris MS, Winkler JL: USPTO 5,571,639.  Computer-
aided engineering system for design of sequence arrays and lithographic
masks . November 5, 1996
17. Powell JW, Lellock KL: Development, Commercialization, and
Diffusion of Enabling Technologies: Progress Report.
Advanced Technology Program, NISTIR 6491 2000:28-29.
18. Ibid :29.
19. Marshall E: Do-It-Yourself Gene Watching.  Science 1999,
286(5439):444-447.
20. For an excellent overview of the history techniques leading to the
development of microarrays, Southern EM: DNA Microarrays:
History and Overview.  In Methods in Molecular Biology. DNA Arrays
Methods and Protocols, Methods  Volume 170. Edited by: Rampal J.
Totawa, NJ: Humana; 2001:1-15. 
21. Schena M, Shalon D, Davis R, Brown P: Quantitative monitoring
of gene expression patterns with a complementary DNA
microarray.  Science 1995, 270(5235):467-470.
22. Shalon D, Smith S, Brown P: A DNA microarray system for ana-
lyzing complex DNA samples using two-color fluorescent
probe hybridization.  Genome Research 1996, 6:639-645.
23. Blanchard A, Kaiser R, Hood L: High density oligonucleotide
arrays.  Biosensors and Bioelectronics 1996, 11:687-690.
24. Southern E: Detection of specific sequences among DNA frag-
ments separated by gel electrophoresis.  J Mol Biol 1975,
98:503-517.
25. Benton W, Davis R: Screening lambda1 recombinant clones by
hybridization to single plaques in situ.  Science 1977,
196:180-182.
26. Kaftos F, Jones C, Efstratiadis A: Determination of nucleic acid
sequence homologies and relative concentrations by a dot
hybridization procedure.  Nucleic Acids Res 1979, 7:1541-1552.
27. Hoheisel J, Ross M, Zehetner G, Lehrach H: Relational genome
analysis using reference libraries and hybridization finger-
printing.  J Biotechnol 1994, 35:121-134.
28. For a full description, Eisen M, Brown P: DNA arrays for analysis
of gene expression.  Methods Enzymol 1999, 303:179-205.
29. Shalon D, Smith S, Brown P: A DNA microarray system for ana-
lyzing complex DNA samples using two-color fluorescent
probe hybridization.  Genome Research 1996, 6:639-645.
30. Schena M, Davis RW: Genes, genomes, and chips.  In DNA Micro-
arrays: A Practical Approach Edited by: Schena M. Oxford: Oxford Univ.
Press; 1999:1-15.  see especially p. 8
31. For a more positive comparison of GeneChips with spotted microar-
rays, Harrington CA, Rosenow C, Retief J: Monitoring gene
expression using DNA microarrays.  Current Opinion in Microbiol-
ogy 2000, 3:285-291.
32. Eisen M, Brown P: DNA arrays for analysis of gene expression.
Methods Enzymol 1999, 303:179-205. especially p. 5, lists the price as
$60,000 including a confocal microscope as part of the detection sys-
tem
33. Cohen WM, Levinthal D: Innovation and Learning: the Two
Faces of R&D.  Economic Journal 1989, 99(September):569-596.
34. Agilent Form 10 K for Fiscal Year 2005.  :10-14. January 17,
2006
35. Schultz PG, Xiang X, Goldwasser I: USPTO 5,776,359.  Giant mag-
netoresistive cobalt oxide compounds . July 7, 1998 (Filed 8 May 1995)Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Biomedical Discovery and Collaboration 2006, 1:11 http://www.j-biomed-discovery.com/content/1/1/11
Page 39 of 39
(page number not for citation purposes)
36. Engstrom J, Weinberg W: Combinatorial Materials Science:
Paradigm Shift in Materials Discovery and Optimization.
AIChE Journal 2000, 46(1):2-5.
37. Ibid .
38. Ibid .
39. Klaerner G, Nielsen RB, Mansky P, Benoit D, Charmot D, Jandeleit B,
Mazzola LT: USPTO 6,833,276.  Polymer brushes for immobilizing
molecules to a surface and having water-soluble or water-dispersible seg-
ments therein andprobes bonded thereto . December 12, 2004
40. Schultz PG, Xiang X, Goldwasser I: USPTO 5,776,359.  Giant mag-
netoresistive cobalt oxide compounds . July 7, 1998 (Filed 8 May 1995)
41. Murphy V, Bei X, Boussie T, Brummer O, Diamond G, Goh C, Hall K,
Lapointe A, Leclerc M, Longmire J, et al.:  High-Throughput
Approaches for the Discovery and Optimization of New Ole-
fin Polymerization Catalysts.  Chemical Record 2002,
2(4):278-289.
42. Symyx website   [http://www.symyx.com]
43. Symyx Form S-1 Registration Statement.  :3. September 21,
1999
44. Alivisatos P: The use of nanocrystals in biological detection.
Nature Biotechnology 2004, 22(Jan):47-52.
45. Each of these two articles announcing the use of quantum dots as bio-
logical labels had been cited approximately 1,000 times as of February,
2006, Bruchez M Jr, Moronne M, Gin P, Weiss S, Alivisatos PA: Sem-
iconductor Nanocrystals as Fluorescent Biological Labels.
Science 1998, 281(25 September):2013-2016.
46. Chan WCW, Nie S: Quantum Dot Bioconjugates for Ultrasen-
sitive Nonisotropic Detection.  Science 1998, 281(September
25):2016-2018.
47. Bawendi MG, Jensen KF: USPTO 6,617,583.  Inventory control . Sep-
tember 9, 2003 (Filed 24 September 1998)
48. Rotman D: Quantum Dot Com.  MIT Technology Review 2002. Jan-
uary
49. Company website and patent reassignment data from the
USPTO.  .
50. We found a great deal of information on university patents licensed
to QDC and subsequent patent reassignments to private investors on
http://assignments.uspto.gov. Financial figures were gath-
ered from press reports.  .
51. RAND Radius and ATP websites: NCI is the National Cancer
Institute, a part of the National Institutes of Health. ATP is
the Advanced Technology Program, which is a part of the
U.S. Department of Commerce.  .
52. Quantum Dot Corporation website   [http://www.Qdots.com]
53. Gilbert W: Towards a paradigm shift in biology.  Nature 1991,
349(6305):99-100.
54. Norberg A, O'Neill JE, Freedman KJ: Transforming Computer Technol-
ogy: Information Processing for the Pentagon, 1962–1986 Baltimore:
Johns Hopkins University Press; 1996. 
55. National Research Council: Funding a Revolution: Government Support
for Computing Research Washington, DC: National Academies Press;
1999. 
56. Toole AA, Czarnitzki D: Biomedical Academic Entrepreneur-
ship Through the SBIR Program.  NBER Working Paper 2005.